ACB Aurora Cannabis Inc

 

 

 

  

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2023

Commission File No. 001-38691

AURORA CANNABIS INC.
(Translation of registrant's name into English)

 

3498 63 Avenue

Leduc, Alberta,T9E 0G8

Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  [ ] Form 40-F  [X]

 

 

 

 

 

 

SUBMITTED HEREWITH

 

Exhibits		Description
99.1		Condensed Consolidated Interim Financial Statements for the three months ended June 30, 2023 and 2022
99.2		Interim Management’s Discussion and Analysis for the three months ended June 30, 2023 and 2022
99.3		Certification of Chief Executive Officer
99.4		Certification of Chief Financial Officer

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AURORA CANNABIS INC.

/s/ Glen Ibbott

Glen Ibbott
Chief Financial Officer

Date: August 10, 2023

Exhibit 99.1

 

 

 

 

 

 

 

 

 

 

AURORA CANNABIS INC.

 

Condensed Consolidated Interim Financial Statements

(Unaudited)

 

 

 

For the three months ended June 30, 2023 and 2022

(in Canadian Dollars)

 

 

 

 

 

 

Table of Contents

Condensed Consolidated Interim Statements of Financial Position	3
Condensed Consolidated Interim Statements of Comprehensive Loss	4
Condensed Consolidated Interim Statements of Changes in Equity	6
Condensed Consolidated Interim Statements of Cash Flows	8
Notes to the Condensed Consolidated Interim Financial Statements

 

Note 1	Nature of Operations	9		Note 12	Share-Based Compensation	19
Note 2	Significant Accounting Policies and Judgments	9		Note 13	Loss per share	22
Note 3	Biological Assets	10		Note 14	Other Gains (Losses)	22
Note 4	Inventory	13		Note 15	Supplemental Cash Flow Information	23
Note 5	Property, Plant and Equipment	13		Note 16	Commitments and Contingencies	24
Note 6	Assets and Liabilities Held for Sale and Discontinued Operations	14		Note 17	Revenue	25
Note 7	Intangible Assets and Goodwill	16		Note 18	Segmented Information	26
Note 8	Convertible Debentures	16		Note 19	Fair Value of Financial Instruments	27
Note 9	Loans and Borrowings	17		Note 20	Financial Instruments Risk	27
Note 10	Lease Liabilities	18		Note 21	Subsequent Events	29
Note 11	Share Capital	18

 

 

	Note	June 30, 2023	March 31, 2023
		$	$
Assets
Current
Cash and cash equivalents		157,855	234,942
Restricted cash	15	65,655	65,900
Accounts receivable	20(a)	32,512	41,308
Income taxes receivable		37	37
Biological assets	3	21,843	22,690
Inventory	4	103,008	106,132
Prepaids and other current assets		9,482	8,280
Assets held for sale	6	8,919	638
		399,311	479,927
Property, plant and equipment	5	307,525	322,969
Derivative assets		7,422	7,249
Deposits and other long-term assets		15,944	15,786
Lease receivable	20(a)	8,140	6,496
Intangible assets	7	59,837	59,680
Goodwill	7	18,715	18,715
Deferred tax assets		15,294	15,500
Total assets		832,188	926,322
Liabilities
Current
Accounts payable and accrued liabilities	20(b)	62,482	75,825
Income taxes payable		446	161
Deferred revenue		1,934	1,739
Convertible debentures	8	65,107	132,571
Loans and borrowings	9	9,439	9,571
Lease liabilities	10	4,906	5,413
Contingent consideration payable	19, 20(b)	10,354	-
Provisions		4,696	4,453
Other current liabilities		12,635	12,572
		171,999	242,305
Loans and borrowings	9	35,111	36,163
Lease liabilities	10	41,821	43,804
Derivative liability	11(c),  12(d)	5,945	9,634
Contingent consideration payable	19, 20(b)	2,610	12,487
Other long-term liability		50,230	48,047
Deferred tax liability		16,540	16,745
Total liabilities		324,256	409,185
Shareholders’ equity
Share capital	11	6,856,255	6,841,234
Reserves		155,674	154,040
Accumulated other comprehensive loss		(210,536)	(212,365)
Deficit		(6,325,661)	(6,296,833)
Total equity attributable to Aurora shareholders		475,732	486,076
Non-controlling interests		32,200	31,061
Total equity		507,932	517,137
Total liabilities and equity		832,188	926,322

Nature of Operations (Note 1)

Commitments and Contingencies (Note 16)

Subsequent Events (Note 21)

 

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

 

		Three months ended June 30,
	Note	2023	2022(1)
		$	$
Revenue	17	81,576	57,455
Excise taxes	17	(6,466)	(7,339)
Net revenue		75,110	50,116
Cost of sales	4	61,407	45,294
Gross profit  before fair value adjustments		13,703	4,822
Changes in fair value of inventory and biological assets sold	4	17,541	22,349
Unrealized gain on changes in fair value of biological assets	3	(28,873)	(24,657)
Gross profit		25,035	7,130
Expense
General and administration		21,874	30,139
Sales and marketing		12,806	16,276
Acquisition costs		226	3,720
Research and development		1,101	1,991
Depreciation and amortization	5, 7	2,861	11,616
Share-based compensation	12	2,281	3,472
		41,149	67,214
Loss from operations		(16,114)	(60,084)
Other Income (expense)
Legal settlement and contract termination fees		(94)	(931)
Interest and other income		3,351	662
Finance and other costs		(5,335)	(14,929)
Foreign exchange (loss) gain		(3,637)	1,099
Other (losses) gains	14	153	(7,043)
Restructuring charges		(432)	(976)
Impairment of property, plant and equipment	5, 6	-	(78,724)
Impairment of intangible assets and goodwill	7	-	(457,458)
		(5,994)	(558,300)
Loss before taxes		(22,108)	(618,384)
Income tax (expense) recovery
Current		(215)	423
Deferred, net		119	940
		(96)	1,363
Net loss from continuing operations		(22,204)	(617,021)
Net loss from discontinued operations, net of tax	6(b)	(6,127)	(1,755)
Net loss		(28,331)	(618,776)

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

⁽¹⁾ Comparative information has been re-presented due to discontinued operations see Note 6(b).

 

(Continued)

		Three months ended June 30,
	Note	2023	2022(1)
		$	$
Net loss from continuing operations		(22,204)	(617,021)
Net loss from discontinued operations, net of tax	6(b)	(6,127)	(1,755)
Net loss		(28,331)	(618,776)
Other comprehensive loss (“OCI”) that will not be reclassified to net loss
Unrealized gain on marketable securities		-	(982)
Other comprehensive (loss) income that may be reclassified to net loss
Foreign currency translation gain (loss)		1,829	(3,657)
Comprehensive loss from continuing operations		(20,375)	(621,660)
Comprehensive loss from discontinued operations		(6,127)	(1,755)
Comprehensive loss		(26,502)	(623,415)
Net loss from continuing operations attributable to:
Aurora Cannabis Inc.		(20,771)	(617,032)
Non-controlling interests		(1,433)	11
Net loss from discontinued operations attributable to:
Aurora Cannabis Inc.	6(b)	(6,127)	(1,755)
Non-controlling interests		-	-
Comprehensive loss attributable to:
Aurora Cannabis Inc.		(25,069)	(623,426)
Non-controlling interests		(1,433)	11
Loss per share - basic and diluted
Continuing operations	13	($0.06)	($2.48)
Discontinued operations	13	($0.02)	($0.01)
Total operations	13	($0.08)	($2.49)

 

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

⁽¹⁾ Comparative information has been re-presented due to discontinued operations see Note 6(b).

 

		Share Capital			Reserves							AOCI
	Note	Common Shares	Amount		Share-Based Compensation	Compensation Options/ Warrants/Shares Issued	Convertible Notes	Change in Ownership Interest	Obligation to Issue Shares	Total Reserves		Fair Value	Deferred Tax	Associate OCI Pick-up	Foreign Currency Translation	Total AOCI	Deficit	Non-Controlling Interests	Total
		#	$		$	$	$	$	$	$		$	$	$	$	$	$	$	$
Balance, March 31, 2023		345,269,310	6,841,234		212,340	27,667	419	(86,800)	414	154,040		(214,599)	18,919	208	(16,893)	(212,365)	(6,296,833)	31,061	517,137
Shares issued through equity financing		21,272,120	15,687		-	-	-	-	(414)	(414)		-	-	-	-	-	-	-	15,273
Equity financing transaction costs		-	(548)		-	-	-	-	-	-		-	-	-	-	-	-	-	(548)
Deferred tax on transaction costs		-	(120)		-	-	-	-	-	-		-	-	-	-	-	-	-	(120)
Share  issued under RSU, PSU and DSU plans	12(b)(c)	1,463	2		(2)	-	-	-	-	(2)		-	-	-	-	-	-	-	-
Share-based compensation	12	-	-		2,050	-	-	-	-	2,050		-	-	-	-	-	-	-	2,050
Put option liability		-	-		-	-	-	-	-	-		-	-	-	-	-	(1,930)	-	(1,930)
Change in ownership interests in net assets		-	-		-	-	-	-	-	-		-	-	-	-	-	-	2,572	2,572
Comprehensive loss for the period		-	-		-	-	-	-	-	-		-	-	-	1,829	1,829	(26,898)	(1,433)	(26,502)
Balance, June 30, 2023		366,542,893	6,856,255		214,388	27,667	419	(86,800)	-	155,674		(214,599)	18,919	208	(15,064)	(210,536)	(6,325,661)	32,200	507.932

 

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

 

 

 

		Share Capital			Reserves						AOCI
	Note	Common Shares	Amount		Share-Based Compensation	Compensation Options/ Warrants	Convertible Notes	Change in Ownership Interest	Total Reserves		Fair Value	Deferred Tax	Associate OCI Pick-up	Foreign Currency Translation	Total AOCI	Deficit	Non-Controlling Interests	Total
		#	$		$	$	$	$	$		$	$	$	$	$	$	$	$
Balance, March 31, 2022		224,329,745	6,570,995		203,877	27,667	419	(86,800)	145,163		(212,412)	18,919	208	(13,797)	(207,082)	(5,419,488)	500	1,090,088
Shares issued/issuable for business combinations		2,467,421	9,230		-	9,683	-	-	9,683		-	-	-	-	-	-	-	18,913
Shares issued through equity financing	11(b)	70,897,389	184,443		-	-	-	-	-		-	-	-	-	-	-	-	184,443
Share issuance cost		-	(10,132)		-	-	-	-	-		-	-	-	-	-	-	-	(10,132)
Equity financing transaction costs		-	(940)		-	-	-	-	-		-	-	-	-	-	-	-	(940)
Exercise of RSUs, PSUs, and DSUs	12(b),	77,683	1,030		(1,030)	-	-	-	(1,030)		-	-	-	-	-	-	-	-
Share-based compensation (1)	12	-	-		3,397	-	-	-	3,397		-	-	-	-	-	-	-	3,397
Comprehensive loss for the period		-	-		-	-	-	-	-		(982)	-	-	(3,657)	(4,639)	(618,787)	11	(623,415)
Balance,  June 30, 2022		297,772,238	6,754,626		206,244	37,350	419	(86,800)	157,213		(213,394)	18,919	208	(17,454)	(211,721)	(6,038,275)	511	662,354

 

 

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

 

		Three months ended June 30,
	Note	2023	2022(1)
		$	$
Operating activities
Net loss from continuing operations		(22,204)	(617,021)
Adjustments for non-cash items:
Unrealized gain on changes in fair value of biological assets	3	(28,873)	(24,657)
Changes in fair value of inventory and biological assets sold	4	17,541	22,349
Depreciation of property, plant and equipment	5	9,763	12,635
Amortization of intangible assets	7	245	8,319
Share-based compensation		2,281	3,472
Impairment of property, plant and equipment	5, 6	-	78,724
Impairment of intangible assets and goodwill	7	-	457,458
Net interest accrual and accretion	8	3,552	19,241
Deferred tax recovery		(70)	(940)
Other losses (gains)	14	(153)	3,346
Foreign exchange loss		2,129	(3,142)
Restructuring		-	2,731
Deferred compensation amortization		952	-
Changes in non-cash working capital	15	3,814	15,181
Net cash used in operating activities from discontinued operations		(214)	(4,338)
Net cash used in operating activities		(11,237)	(26,642)
Investing activities
Loan receivable		-	(16)
Purchase of property, plant and equipment and intangible assets	5, 7	(4,297)	(5,900)
Proceeds from disposal  of property, plant and equipment and assets held for sale	6	2,394	(4,938)
Acquisition of businesses, net of cash acquired		-	(24,467)
Payment of contingent consideration		-	(98)
Deposits (paid) received		-	(1,155)
Net cash used by investing activities from discontinued operations		(255)	(3,162)
Net cash used in investing activities		(2,158)	(39,736)
Financing activities
Repayment of long-term loans	9	(516)	-
Repayment of convertible debenture	8	(61,867)	(145,650)
Net payments of principal portion of lease liabilities	10	(1,438)	(1,845)
Restricted cash	15	245	(314)
Shares issued for cash, net of share issue costs		1,722	209,933
Net cash used in financing activities from discontinued operations		(89)	(85)
Net cash provided by (used in) financing activities		(61,943)	62,039
Effect of foreign exchange on cash and cash equivalents		(1,749)	12,252
Increase (decrease) in cash and cash equivalents		(77,087)	7,913
Cash and cash equivalents, beginning of period		234,942	429,894
Cash and cash equivalents, end of period		157,855	437,807

Supplemental cash flow information (Note 15)

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

⁽¹⁾ Comparative information has been re-presented due to discontinued operations see Note 6(b).

Note 1 Nature of Operations

 

Aurora Cannabis Inc. (the “Company” or “Aurora”) was incorporated under the Business Corporations Act (British Columbia) on December 21, 2006 as Milk Capital Corp. Effective October 2, 2014, the Company changed its name to Aurora Cannabis Inc. The Company’s shares are listed on the Nasdaq Global Select Market (“Nasdaq”) and the Toronto Stock Exchange (“TSX”) under the trading symbol “ACB”, and on the Frankfurt Stock Exchange (“FSE”) under the trading symbol “21P1”.

 

The Company’s head office and principal address is 3498 - 63 Avenue, Leduc, Alberta, Canada, T9E 0G8. The Company’s registered and records office address is Suite 1700, 666 Burrard Street, Vancouver, British Columbia, Canada, V6C 2X8.

 

The Company’s principal strategic business lines are focused on the production, distribution and sale of cannabis related products in Canada and internationally. Aurora currently conducts the following key business activities in the jurisdictions listed below:

 

•

Production, distribution and sale of medical and consumer cannabis products in Canada pursuant to the Cannabis Act;

•

Distribution of wholesale medical cannabis in the European Union (“EU”) pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and

•

Distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America and Israel.

 

Note 2 Significant Accounting Policies and Judgments

 

(a)       Basis of Presentation and Measurement

 

The condensed interim consolidated interim financial statements of the Company have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and International Accounting Standards 34, Interim Financial Reporting (“IAS 34”) as issued by the International Accounting Standards Board (“IASB”), and interpretations of the IFRS Interpretations Committee (“IFRIC”). Unless otherwise noted, all amounts are presented in thousands of Canadian dollars, except share and per share data.

 

The condensed consolidated interim financial statements are presented in Canadian dollars and are prepared in accordance with the same accounting policies, critical estimates and methods described in the Company’s annual consolidated financial statements, except for the adoption of new accounting policies (Note 2(d)). Given that certain information and footnote disclosures, which are included in the annual audited consolidated financial statements, have been condensed or excluded in accordance with IAS 34, these condensed consolidated interim financial statements should be read in conjunction with our annual audited consolidated financial statements as at and for the year ended March 31, 2023, including the accompanying notes thereto.

 

(b)       Basis of Consolidation

 

The condensed interim consolidated financial statements include the financial results of the Company and its subsidiaries. Subsidiaries include entities which are wholly-owned as well as entities over which Aurora has the authority or ability to exert power over the investee’s financial and/or operating decisions (i.e. control), which in turn may affect the Company’s exposure or rights to the variable returns from the investee. The consolidated interim financial statements include the operating results of acquired or disposed entities from the date control is obtained or the date control is lost, respectively. All intercompany balances and transactions are eliminated upon consolidation.

 

The Company’s principal subsidiaries during the three months ended June 30, 2023 are as follows:

Major subsidiaries	Percentage Ownership	Functional Currency
2105657 Alberta Inc. (“2105657”)	100%	Canadian Dollar
Aurora Cannabis Enterprises Inc. (“ACE”)	100%	Canadian Dollar
Aurora Deutschland GmbH (“Aurora Deutschland”)	100%	European Euro
Aurora Nordic Cannabis A/S (“Aurora Nordic”)	100%	Danish Krone
Reliva, LLC (“Reliva”)	100%	United States Dollar
TerraFarma Inc.	100%	Canadian Dollar
Whistler Medical Marijuana Corporation (“Whistler”)	100%	Canadian Dollar
Bevo Agtech Inc.	50.1%	Canadian Dollar
CannaHealth Therapeutics Inc.	100%	Canadian Dollar
ACB Captive Insurance Company Inc.	100%	Canadian Dollar

 

All shareholdings are of ordinary shares or other equity. Other subsidiaries, while included in the consolidated financial statements, are not material and have not been reflected in the table above.

 

  

 

 

(c) Discontinued operations

 

The Company reports financial results for discontinued operations separately from continuing operations to distinguish the financial impact of disposal transactions from ongoing operations. Discontinued operations reporting occurs when the disposal of a component or a group of components of the Company represents a strategic shift that will have an impact on the Company’s operations and financial results, and where the operations and cash flows can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the Company.

 

The results of discontinued operations are excluded from both continuing operations and business segment information in the condensed consolidated interim financial statements and the notes to the consolidated financial statements, unless otherwise noted, and are presented net of tax in the consolidated statements of loss and comprehensive income (loss) for the current and comparative periods. Refer to Note 6(b) Discontinued Operations.

 

(d)

Adoption of New Accounting Pronouncements

 

Amendments to IAS 1: Classification of Liabilities as Current or Non-current

 

The amendment clarifies the requirements relating to determining if a liability should be presented as current or non-current in the statement of financial position. Under the new requirement, the assessment of whether a liability is presented as current or non-current is based on the contractual arrangements in place as at the reporting date and does not impact the amount or timing of recognition. The amendment applies retrospectively for annual reporting periods beginning on or after January 1, 2023. There were no changes to the Company’s current period or comparative period upon adoption.

 

Amendments to IAS 12: Income Taxes

 

The amendment clarifies how companies account for deferred tax on transactions such as leases and decommissioning obligations. The amendments are effective for annual periods beginning on or after January 1, 2023. There was no material impact as a result of adopting these amendments.

 

Amendments to IAS 12: Deferred Tax related to Assets and Liabilities arising from a Single Transaction

 

The amendment narrowed the scope of certain recognition exemptions so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences. An entity applies the amendments to transactions that occur on or after the beginning of the earliest comparative period presented. It also, at the beginning of the earliest comparative period presented, recognizes deferred tax for all temporary differences related to leases and decommissioning obligations and recognizes the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings (or other component of equity, as appropriate) at that date. The amendment is effective for annual periods beginning on or after January 1, 2023 with early application permitted. The Company early adopted these amendments with the adoption of IFRS 16, Leases and therefore there are no changes to the current and comparative periods presented in the consolidated financial statements. The Company has not had any decommissioned obligations to account for hereunder.

 

IFRS 17 - Insurance Contracts

 

IFRS 17 establishes the principles for the recognition, measurement, presentation and disclosure of insurance contracts within the scope of the standard. The objective of IFRS 17 is to ensure that an entity provides relevant information that faithfully represents those contracts. The standard is effective for annual periods beginning on or after January 1, 2023. The Company does not currently have any contracts to be accounted for under this standard. The Company, however has a wholly owned captive insurance entity that is required to adopt this standard when reporting on a standalone basis. The impact of the captive insurance company adopting IFRS 17 was immaterial to the Company’s consolidated financial statements.

 

Amendments to IAS 16: Leases

 

The amendment clarifies how a seller-lessee subsequently measures sale and leaseback transactions that satisfy the requirements in

IFRS 15: Revenue to be accounted for as a sale. The amendment is effective for annual periods beginning on or after January 1, 2024. The Company does not have any sale-leaseback transactions.

 

(e)

New Accounting Pronouncements Not Yet Adopted

 

The following IFRS standards have been recently issued by the IASB. Pronouncements that are irrelevant or not expected to have a significant impact have been excluded.

 

Amendments to IAS 1: Covenants

 

The amendment that clarify how an entity classifies debt and other financial liabilities as current or non-current in particular circumstances. The amendments are effective for annual periods beginning on or after January 1, 2024. Management is currently evaluating the potential impact of this standard on the Company’s consolidated financial statements.

 

 

 

Note 3 Biological Assets

 

The following is a breakdown of biological assets:

 

	June 30, 2023	March 31, 2023
	$	$
Indoor cannabis production facilities	14,596	8,428
Outdoor cannabis production facilities	1,816	-
Plant propagation production facilities	5,431	14,262
	21,843	22,690

 

The changes in the carrying value of biological assets during the period are as follows:

	$
Balance, March 31, 2023	22,690
Production costs capitalized	18,905
Sale of biological assets	(14,557)
Impairment related to discontinued operations	(1,032)
Foreign currency translation	(10)
Changes in fair value less cost to sell due to biological transformation	28,873
Transferred to inventory upon harvest	(33,026)
Balance, June 30, 2023	21,843

 

a) Indoor cannabis production facilities

 

The following inputs and assumptions are all categorized within Level 3 on the fair value hierarchy and were used in determining the fair value of indoor cannabis biological assets:

Inputs and assumptions	Description	Correlation between inputs and fair value
Average selling price per gram	Represents the average selling price per gram of dried cannabis net of excise taxes, where applicable, for the period for all strains of cannabis sold, which is expected to approximate future selling prices.	If the average selling price per gram were higher (lower), estimated fair value would increase (decrease).
Average attrition rate	Represents the weighted average number of plants culled at each stage of production.	If the average attrition rate was lower (higher), estimated fair value would increase (decrease).
Weighted average yield per plant	Represents the weighted average number of grams of dried cannabis inventory expected to be harvested from each cannabis plant.	If the weighted average yield per plant was higher (lower), estimated fair value would increase (decrease).
Standard cost per gram to complete production	Based on actual production costs incurred divided by the grams produced in the period.	If the standard cost per gram to complete production was lower (higher), estimated fair value would increase (decrease).
Weighted average effective yield	Represents the estimated percentage of harvested product that meets specifications in order to be sold as a dried cannabis product.	If the weighted average effective yield were higher (lower), the estimated fair value would increase (decrease).
Stage of completion in the production process	Calculated by taking the weighted average number of days in production over a total average grow cycle of approximately twelve weeks.	If the number of days in production was higher (lower), estimated fair value would increase (decrease).

 

 

 

The following table highlights the sensitivities and impact of changes in significant assumptions on the fair value of biological assets grown at indoor cannabis production facilities:

 

Significant inputs & assumptions	Range of inputs		Sensitivity	Impact on fair value
	June 30, 2023	March 31, 2023		June 30, 2023	March 31, 2023
Average selling price per gram	$5.05	$4.42	Increase or decrease of $1.00 per gram	$3,738	$3,360
Weighted average yield (grams per plant)	57.18	38.80	Increase or decrease by 5 grams per plant	$1,247	$1,438
Weighted average effective yield	87 %	91 %	Increase of decrease by 5%	$813	$395
Cost per gram to complete production	$1.22	$1.65	Increase or decrease of $1.00 per gram	$3,826	$3,427

 

As of June 30, 2023, the weighted average fair value less cost to complete and cost to sell a gram of dried cannabis produced at the Company’s indoor cannabis cultivation facilities was $3.24 per gram (March 31, 2023 - $2.43 per gram).

 

During the three months ended June 30, 2023, the Company’s indoor cannabis biological assets produced 9,585 kilograms of dried cannabis (June 30, 2022 - 16,109 kilograms). As at June 30, 2023, it is expected that the Company’s indoor cannabis biological assets will yield approximately 9,501 kilograms (March 31, 2023 - 7,667 kilograms) of dried cannabis when harvested and the weighted average stage of growth for indoor biological assets was 46% (March 31, 2023 - 44%).

 

b) Plant propagation production facilities

 

The following table highlights the sensitivities and impact of changes in significant assumptions on the fair value of biological assets grown at plant propagation production facilities:

 

Significant inputs & assumptions	Range of inputs		Sensitivity	Impact on fair value
	June 30, 2023	March 31, 2023		June 30, 2023	March 31, 2023
Average selling price per floral/bedding plant	$ 9.89	$7.58	Increase or decrease by 10%	$392	$1,682
Average stage of completion in the production process	27 %	56 %	Increase or decrease by 10%	$791	$2,295

 

As of June 30, 2023, the weighted average fair value less cost to complete and cost to sell per propagation plant was $2.06 per plant (March 31, 2023 - $2.35).

 

During the three months ended June 30, 2023, biological assets relating to the plant propagation segment was expensed to cost of goods sold was $14.6 million (three months ended June 30, 2022 - nil), which included $1.7 million (three months ended June 30, 2022 - nil) of non-cash expense related to the changes in fair value of biological assets sold.

 

Note 4 Inventory

 

The following is a breakdown of inventory:

	June 30, 2023			March 31, 2023
	Capitalized cost	Fair value adjustment	Carrying value	Capitalized cost	Fair value adjustment	Carrying value
	$	$	$	$	$	$
Harvested cannabis
Work-in-process	28,090	18,467	46,557	30,936	14,756	45,692
Finished goods	13,587	1,979	15,566	13,518	1,777	15,295
	41,677	20,446	62,123	44,454	16,533	60,987
Extracted cannabis
Work-in-process	10,870	3,262	14,132	11,566	2,753	14,319
Finished goods	7,414	765	8,179	8,786	561	9,347
	18,284	4,027	22,311	20,352	3,314	23,666
Supplies and consumables	16,543	-	16,543	19,923	-	19,923
Merchandise and accessories	2,031	-	2,031	1,556	-	1,556
Ending balance	78,535	24,473	103,008	86,285	19,847	106,132

 

During the three months ended June 30, 2023, inventory expensed to cost of goods sold was $64.4 million (three months ended June 30, 2022 - $67.6 million), which included $15.9 million (three months ended June 30, 2022 - $22.5 million) of non-cash expense related to the changes in fair value of inventory sold.

 

During the three months ended June 30, 2023, the Company recognized $10.4 million (three months ended June 30, 2022 - $15.3 million) in changes in fair value of inventory sold and $8.9 million (three months ended June 30, 2022 - $11.3 million) recognized in cost of sales in the condensed consolidated statements of loss and comprehensive loss.

 

Note 5 Property, Plant and Equipment

 

The following summarizes the carrying values of property, plant and equipment for the periods reflected:

	June 30, 2023				March 31, 2023
	Cost	Accumulated depreciation	Impairment	Net book value	Cost	Accumulated depreciation	Impairment	Net book value
Owned assets
Land	42,398	-	-	42,398	52,077	-	(1,820)	50,257
Buildings	237,875	(88,644)	-	149,231	239,353	(83,888)	(3,842)	151,623
Construction in progress	27,447	-	-	27,447	37,563	-	(11,945)	25,618
Computer software & equipment	31,224	(29,797)	-	1,427	31,313	(29,570)	(20)	1,723
Furniture & fixtures	7,605	(5,853)	-	1,752	7,434	(5,596)	(42)	1,796
Production & other equipment	143,005	(88,890)	-	54,115	146,960	(87,425)	(1,686)	57,849
Total owned assets	489,554	(213,184)	-	276,370	514,700	(206,479)	(19,355)	288,866
Right-of-use lease assets
Land	13,890	(1,409)	-	12,481	14,859	(1,345)	(969)	12,545
Buildings	33,814	(15,564)	-	18,250	36,789	(15,836)	-	20,953
Production & other equipment	5,181	(4,757)	-	424	5,343	(4,738)	-	605
Total right-of-use lease assets	52,885	(21,730)	-	31,155	56,991	(21,919)	(969)	34,103
Total property, plant and equipment	542,439	(234,914)	-	307,525	571,691	(228,398)	(20,324)	322,969

 

 

The following summarizes the changes in the net book values of property, plant and equipment for the periods presented:

	Balance, March 31, 2023	Additions	Disposals	Other (1)	Depreciation	Foreign currency translation	Balance, June 30, 2023
Owned assets
Land	50,257	-	-	(7,647)	-	(212)	42,398
Buildings	151,623	288	-	488	(3,308)	140	149,231
Construction in progress	25,618	2,937	-	(756)	(145)	(207)	27,447
Computer software & equipment	1,723	18	-	(3)	(305)	(6)	1,427
Furniture & fixtures	1,796	264	-	(5)	(283)	(20)	1,752
Production & other equipment	57,849	167	(27)	1,063	(4,789)	(148)	54,115
Total owned assets	288,866	3,674	(27)	(6,860)	(8,830)	(453)	276,370
Right-of-use leased assets
Land	12,545	-	-	-	(64)	-	12,481
Buildings	20,953	-	(1,886)	-	(780)	(37)	18,250
Production & other equipment	605	-	(68)	-	(89)	(24)	424
Total right-of-use lease assets	34,103	-	(1,954)	-	(933)	(61)	31,155
Total property, plant and equipment	322,969	3,674	(1,981)	(6,860)	(9,763)	(514)	307,525

(1)

Includes reclassification of construction in progress cost when associated projects are complete. Includes the transfer of facilities to assets held for sale as at June 30, 2023 (Note 6).

 

Depreciation relating to manufacturing equipment and production facilities for owned and right-of-use leased assets is capitalized into biological assets and inventory, and is expensed to cost of sales upon the sale of goods. During the three months ended June 30, 2023, the Company recognized $9.8 million (June 30, 2022 - $14.5 million) of depreciation expense of which $5.4 million ( June 30, 2022 - $6.8 million) was reflected in cost of sales.

 

Note 6 Assets Held for Sale and Discontinued Operations

 

(a)       Assets and Liabilities Held for Sale

 

Assets held for sale are comprised of the following:

	Whistler Alpha Lake	European  R&D Facility	Growery	Total
Balance, March 31, 2023	638	-	-	638
Transfer from Property, Plant, and Equipment	-	2,234	6,685	8,919
Proceeds from disposal	(2,270)	-	-	(2,270)
Gain on disposal	1,632	-	-	1,632
Balance, June 30, 2023	-	2,234	6,685	8,919

 

Whistler Alpha Lake

 

In connection with the restructuring announced during the year ended June 30, 2022, the Company listed its Whistler Alpha Lake facility for sale. As a result, the Company reclassified property, plant, and equipment of $0.6 million to assets held for sale. During the three months ended June 30, 2023, the facility was sold for net proceeds of $2.3 million. The Company recognized a gain of $1.6 million on disposal, which is recognized in other gains (losses) in the consolidated statements of loss and comprehensive loss (Note 14).

 

European R&D Facility

 

During the three months ended June 30, 2023, the Company decided to sell a European R&D Facility. As a result, the Company reclassified the related property, plant, and equipment of $2.2 million to assets held for sale.

 

 

Growery

 

During the three months ended June 30, 2023, the Company made the decision to exit the agreement with its partners in Growery B.V (“Growery”), one of the license holders entitled to participate in the Netherlands’ still-pending Controlled Cannabis Supply Chain Experiment. As a result, the Company reclassified the related assets from property, plant, and equipment of $6.7 million to assets held for sale.

 

(b)

Discontinued Operations

 

During the three months ended June 30, 2023, the Company formally made the decision to close its Aurora Nordic facility (“Nordic”), located in Denmark due to a number of operational and regulatory challenges.

 

In connection with the closures of Nordic and Growery, the Company has reported these as discontinued operations as the operations and cash flows can be clearly distinguished, operationally and for financial reporting purposes from the rest of the Company.

 

The following table summarizes the Company's consolidated discontinued operations for the respective periods:

 

	Three months ended June 30, 2023	Three months ended June 30, 2022
Revenue	78	99
Cost of sales	2,657	1,966
Changes in fair value of inventory and biological assets sold	274	2,850
Unrealized gain on changes in fair value of biological assets	764	(1,977)
General and administration expenses	459	375
Sales and marketing	69	101
Research and development	126	465
Depreciation	(350)	136
Stock based compensation	-	-
Finance costs	(223)	(158)
Foreign exchange	(18)	(1,904)
Impairment of property, plant, and equipment	85	-
Deferred tax	(49)	-
Loss on disposal of discontinued operations	2,411	-
	6,205	1,854
Net loss from discontinued operations	(6,127)	(1,755)

 

 

 

Note 7 Intangible Assets and Goodwill

 

The following is a continuity schedule of intangible assets and goodwill:

	June 30, 2023				March 31, 2023
	Cost	Accumulated amortization	Impairment	Net book value	Cost	Accumulated amortization	Impairment	Net book value
Definite life intangible assets:
Customer relationships	42,529	(37,138)	-	5,391	42,529	(37,068)	-	5,461
Permits and licenses	54,017	(42,957)	-	11,060	56,782	(42,826)	(2,783)	11,173
Patents	931	(775)	-	156	928	(771)	-	157
Intellectual property and know-how	52,590	(52,590)	-	-	52,590	(52,590)	-	-
Software	17,532	(16,404)	-	1,128	20,121	(16,390)	(3,460)	271
Indefinite life intangible assets:
Brand	20,700	-	-	20,700	36,200	-	(15,500)	20,700
Permits and licenses	21,402	-	-	21,402	21,918	-	-	21,918
Total intangible assets	209,701	(149,864)	-	59,837	231,068	(149,645)	(21,743)	59,680
Goodwill	18,715	-	-	18,715	19,465	-	(750)	18,715
Total	228,416	(149,864)	-	78,552	250,533	(149,645)	(22,493)	78,395

 

The following summarizes the changes in the net book value of intangible assets and goodwill for the periods presented:

	Balance, March 31, 2023	Additions	Amortization	Foreign currency translation	Balance, June 30, 2023
Definite life intangible assets:
Customer relationships	5,461	-	(70)	-	5,391
Permits and licenses	11,173	-	(156)	43	11,060
Patents	157	7	(5)	(3)	156
Software	271	871	(14)	-	1,128
Indefinite life intangible assets:
Brand	20,700	-	-	-	20,700
Permits and licenses (1)	21,918	-	-	(516)	21,402
Total intangible assets	59,680	878	(245)	(476)	59,837
Goodwill	18,715	-	-	-	18,715
Total	78,395	878	(245)	(476)	78,552

(1)

Indefinite life permits and licenses are predominantly held by the Company’s foreign subsidiaries. Given that these permits and licenses are connected to the subsidiary rather than a specific asset, there is no foreseeable limit to the period over which these assets are expected to generate future cash inflows for the Company.

 

As at June 30, 2023, $20.7 million and $21.4 million indefinite life intangibles were allocated to the group of cash generating units (“CGUs”) that comprise the Canadian Cannabis Segment and European Cannabis Segment, respectively (March 31, 2023 - $20.7 million and $21.9 million respectively).

 

Note 8 Convertible Debentures

 

	$
Balance, March 31, 2023	132,571
Interest paid	(553)
Accretion	2,501
Accrued interest	1,174
Amortized cost of debt repurchased	(68,741)
Unrealized gain on foreign exchange	(1,845)
Balance, June 30, 2023	65,107

 

 

 

On January 24, 2019, the Company issued $460.6 million (US$345.0 million) in aggregate principal amount of Convertible Senior Notes due 2024 (“Senior Notes”) issued at par value. Holders may convert all or any portion of the Senior Notes at any time. The Senior Notes are unsecured, mature on February 28, 2024 and bear cash interest semi-annually at a rate of 5.5% per annum. The initial conversion rate for the Senior Notes is 11.53 Common Shares per US$1,000 principal amount of Senior Notes, equivalent to an initial conversion price of approximately US$86.72 per Common Share. As of June 30, 2023, $70.0 million (US$52.8 million) principal amount of the Senior Notes are outstanding.

 

In accordance with IFRS 9, the equity conversion option embedded in the Senior Notes was determined to be a derivative liability, which has been recognized separately at its fair value. Subsequent changes in the fair value of the equity conversion option are recognized through profit and loss (i.e. FVTPL). The equity conversion option was classified as an option liability as it can be settled through the issuance of a variable number of shares, cash or a combination thereof, based on the exchange rate and or trading price at the time of settlement.

 

As of June 30, 2023, the conversion option had a fair value of $nil (March 31, 2023 - $nil) and the Company recognized an unrealized gain of $nil for the three months ended June 30, 2023 (three months ended June 30, 2022 - $3.1 million) on the derivative liability. The fair value of the conversion option was determined based on the Kynex valuation model with the following assumptions: share price of US$0.53 (March 31, 2023 - US$0.70), volatility of 84% (March 31, 2023 - 84%), implied credit spread of 420 bps (March 31, 2023 - 397 bps), and assumed stock borrow rate of 10% (March 31, 2023 - 10%). As of June 30, 2023, the Company has accrued interest payable of $16.9 million (March 31, 2023 - $16.9 million) on the Senior Notes.

 

During the three months ended June 30, 2023 the Company repurchased a total of $76.9 million (US$57.0 million) (three months ended June 30, 2022 - $155.3 million (US$113.9 million) ) in principal amount of the Senior Notes at a total cost, including accrued interest, of $75.7 million (US $56.2 million) (three months ended June 30, 2022 - $149.2 million (US $115.3 million)) and recognized a loss of $5.9 million (three months ended June 30, 2022 - $18.3 million) within other gains (losses) in the statements of loss and comprehensive loss.

 

The convertible senior notes, were repurchased at a 2.3% average discount to par value, for aggregate cash consideration of approximately $61.9 million (U.S$46.0 million) and the issuance of 18,691,770 Common Shares.

 

Note 9 Loans and Borrowings

 

Through its acquisition of Bevo Farms Ltd (“Bevo”), a 50.1% owned subsidiary in the plant propagation business during fiscal 2023, the Company acquired a term loan and revolver, together, the credit facilities (the “Credit Agreement”).

 

The changes in the carrying value of current and non-current term loan credit facilities are as follows:

	Term loan credit facilities
	$
Balance, March 31, 2023	45,734
Accretion	130
Interest payments	(798)
Principal repayments	(516)
Balance, June 30, 2023	44,550
Current portion	(9,439)
Long-term portion	35,111

On April 11, 2023, the Credit Agreement was amended to reduce the amounts available to be drawn from the Term Loan by $9.7 million to $38.1 million and increase the amounts available to be drawn from the Revolver by $4.0 million to $12.0 million. Additionally, there were changes to the financial covenants. There were nominal costs incurred for the amendments.

The term loans consist of the following access to funds under the credit facility:

i.

a $38.1 million term loan (“Term Loan”), previously $47.8 million; and

ii.

a $12.0 million revolving line of credit (“Revolver”), previously $8.0 million.

 

Under the terms of the Credit Agreement, the Company is subject to certain customary financial and non-financial covenants and restrictions. In addition, the Credit Agreement is secured by a first-ranking security interest over substantially all the property of Bevo Farms Ltd. and its subsidiaries. As at June 30, 2023, the Company was in compliance with all covenants relating to the Credit Agreement.

 

Term loan

 

As at June 30, 2023, advances under the Term Loan were made in two tranches, with interest payments based on prime rate plus a margin. Interest is due monthly and the principal balance is repayable in equal quarterly installments of 1/60th of the amount borrowed. As at June 30, 2023, the borrowing rate was 4.905%. Each tranche is scheduled to mature on January 21, 2025. Any remaining principal balance will be due at maturity. During the three months ended June 30, 2023, total interest expense of $0.6 million was recognized as finance and other costs in the condensed consolidated interim statements of loss and comprehensive loss. As at June 30, 2023, the total term loan payable is $37.1 million.

 

Revolver

 

The Revolver provides available aggregate borrowings of up to $12.0 million. Interest payments are based on prime plus a margin that ranges between 0.25% and 1.75%. As at June 30, 2023, $7.3 million was drawn from the revolver loan.

 

Total loans and borrowings principal repayments as at June 30, 2023 are as follows:

 

	$
Next 12 months	9,439
Over 1 year to 3 years	2,639
Over 3 years to 5 years	6,766
Over 5 years	25,706
Total long-term debt repayments	44,550

 

Note 10 Lease liabilities

 

The changes in the carrying value of current and non-current lease liabilities are as follows:

		$
Balance, March 31, 2023		49,217
Disposal of leases		(86)
Lease payments		(2,146)
Net lease term increase and other items		(955)
Changes due to foreign exchange rates		(85)
Interest expense on lease liabilities		782
Balance, June 30, 2023		46,727
Current portion		(4,906)
Long-term portion		41,821

 

Note 11 Share Capital

 

(a)

Authorized

 

The authorized share capital of the Company is comprised of the following:

 

i.

Unlimited number of common voting shares without par value.

ii.

Unlimited number of Class “A” Shares each with a par value of $1.00. As at June 30, 2023, no Class “A” Shares were issued and outstanding.

iii.

Unlimited number of Class “B” Shares each with a par value of $5.00. As at June 30, 2023, no Class “B” Shares were issued and outstanding.

 

(b)

Shares Issued and Outstanding

 

At June 30, 2023, 366,542,893 Common Shares (March 31, 2023 - 345,269,310) were issued and fully paid.

 

(c)

Share Purchase Warrants

 

A summary of warrants outstanding is as follows:

	Warrants	Weighted average exercise price
	#	$
Balance, March 31, 2023	89,124,788	7.09
Balance, June 30, 2023	89,124,788	6.89

 

In accordance with IAS 32 - Financial Instruments: Presentation, the June 2022 Offering Warrants were determined to be derivative liabilities as the proceeds receivable upon exercise may vary due to fluctuations in the foreign exchange rates. The June 2022 Offering Warrants are recognized at their fair values based on quoted market prices with gains and losses recognized in other gains (losses) (Note 14) on the condensed consolidated statements of comprehensive loss.

 

In accordance with IAS 32 - Financial Instruments: Presentation, the November 2020 and January 2021 Offering Warrants, which are denominated in U.S. Dollars, were determined to be derivative liabilities as the proceeds receivable upon exercise may vary due to fluctuations in the foreign exchange rates. The Offering Warrants are recognized at their fair values based on quoted market prices with gains and losses recognized in other (losses) gains (Note 14) on the condensed consolidated statements of comprehensive loss.

 

The following summarizes the warrant derivative liabilities:

 

						US$ equivalent
	November 2020 Offering	January 2021 Offering	June 2022 Offering	Total		November 2020 Offering	January 2021 Offering	June 2022 Offering	Total
	$	$	$	$		$	$	$	$
Balance, March 31, 2023	75	45	9,514	9,634		54	33	7,041	7,128
Unrealized (loss) gain on derivative liability	(1)	(1)	(3,918)	(3,920)		-	-	(2,816)	(2,816)
Balance, June 30, 2023	74	44	5,596	5,714		54	33	4,225	4,312

 

The following table summarizes the warrants that remain outstanding as at June 30, 2023:

Exercise Price ($)	Expiry Date	Warrants (#)
4.24 - 41.88 (2)	January 26, 2024 - November 30, 2025	88,596,596
112.46 - 116.09 (1)	August 9, 2023 to August 22, 2024	528,192
		89,124,788

(1)

Includes the November 2020 and January 2021 Offering Warrants exercisable at US$9.00 and US$12.60, respectively.

(2)

Includes the June 2022 Offering Warrants exercisable at US$3.20.

 

Note 12 Share-Based Compensation

 

(a)

Stock Options

 

A summary of stock options outstanding is as follows:

	Stock Options	Weighted Average Exercise Price
	#	$
Balance, March 31, 2023	6,721,503	25.73
Granted	6,334,852	0.76
Expired	(50,142)	96.15
Forfeited	(473,454)	10.03
Balance, June 30, 2023	12,532,759	13.42

 

 

The following table summarizes the stock options that are outstanding as at June 30, 2023:

Exercise Price ($)	Expiry Date	Weighted Average Remaining Life	Options Outstanding (#)	Options Exercisable (#)
0.76 - 27.24	January 10, 2025 - June 23, 2028	4.44	11,348,864	1,669,927
38.52 - 99.60	July 17, 2023 - December 9, 2024	0.67	324,551	324,551
100.80 - 133.80	July 12, 2023 - July 12, 2024	2.26	791,179	791,179
135.00 - 156.36	September 25, 2023 - May 21, 2024	0.65	68,165	68,165
		4.14	12,532,759	2,853,822

 

During the three months ended June 30, 2023, the Company recorded aggregate share-based compensation expense of $0.5 million (three months ended June 30, 2022 - $1.3 million) for all stock options granted and vested during the period. This expense is reflected in the share-based compensation line on the condensed consolidated statements of comprehensive loss.

 

Stock options granted during the respective periods highlighted below were fair valued based on the following weighted average assumptions:

 

	Three months ended June 30, 2023	Three months ended June 30, 2022
Risk-free annual interest rate (1)	4.34%	2.65%
Expected annual dividend yield	- %	- %
Expected stock price volatility (2)	85.06%	87.49%
Expected life of options (years) (3)	2.67	2.50
Forfeiture rate	19.63%	19.82%

(1)

The risk-free rate is based on Canada government bonds with a remaining term equal to the expected life of the options.

(2)

Volatility was estimated by using the average historical volatilities of the Company and certain competitors.

(3)

The expected life in years represents the period of time that options granted are expected to be outstanding.

 

The weighted average fair value of stock options granted during the three months ended June 30, 2023 was $0.41 per option (three months ended June 30, 2022 - $1.25 per option).

 

(b)

Restricted Share Units (“RSU”) and Deferred Share Units (“DSU”)

 

A summary of the RSUs and DSUs outstanding are as follows:

	RSUs and DSUs	Weighted Average Issue Price of RSUs and DSUs
	#	$
Balance, March 31, 2023	7,524,940	2.64
Issued (1)	3,818,348	0.76
Vested, released and issued	(4,424)	9.68
Forfeited	(724,125)	2.28
Balance, Jun 30, 2023(2)	10,614,739	1.99

(1)

Includes DSUs issued under cash settlement plan Note 12(d)

(2)

As of June 30, 2023, there were 9,309,550 RSUs and 1,305,189 DSUs outstanding (March 31, 2023 - 6,614,487 RSUs and 910,453 DSUs).

 

During the three months ended June 30, 2023, the Company recorded share-based compensation of $1.6 million (three months ended June 30, 2022 - $1.8 million) for RSUs and DSUs granted and vested during the period. This expense is included in the share-based compensation line on the condensed consolidated statements of comprehensive loss.

 

The weighted average fair value of RSUs and DSUs granted in the three months ended June 30, 2023 was $0.76 per unit (three months ended June 30, 2022 - $2.53 per unit).

 

The following table summarizes the RSUs and DSUs that are outstanding as at June 30, 2023:

Weighted Average Issue Price ($)	Expiry Date	Outstanding (#)	Vested (#)
$0.76 - $8.50	Nov 3, 2023 - June 23, 2026	10,371,097	1,406,470
$10.09 - $21.72	Sept. 10, 2023 - Feb 16, 2024	239,513	121,118
$90.12 - $113.16	N/A	4,129	4,129
		10,614,739	1,531,717

 

(c)

Performance Share Units (“PSUs”)

 

A summary of the PSUs outstanding is as follows:

 

	PSUs	Weighted Average Issue Price of PSUs
	#	$
Balance, March 31, 2023	2,308,221	3.77
Issued (1)	5,229,068	0.76
Vested, released and issued	(258)	1.87
Forfeited	(214,002)	3.93
Balance, June 30, 2023	7,323,029	1.62

(1)

Includes PSUs issued under cash settlement plan Note 12(d)

 

 

The following table summarizes the PSUs that are outstanding as at June 30, 2023:

Weighted Average Issue Price ($)	Expiry Date	Outstanding (#)	Vested (#)
$0.76 - $8.50	Sept 10, 2023 - June 23, 2026	7,081,159	302
$10.09 - $13.59	Sept 10, 2023 - Dec. 09, 2023	241,870	-
		7,323,029	302

 

During the three months ended June 30, 2023, the Company recorded share-based compensation of $0.2 million (three months ended June 30, 2022 - $1.4 million), for PSUs granted during the period. This expense is included in the share-based compensation line on the condensed consolidated statements of comprehensive loss.

 

PSUs granted during the respective periods highlighted below were fair valued based on the following weighted average assumptions:

	Three months ended June 30, 2023	Three months ended June 30, 2022
Risk-free annual interest rate (1)	4.76%	1.23%
Dividend yield	- %	- %
Expected stock price volatility (2)	90.65%	38.23%
Expected stock price volatility of peer group (2)	91.51%	28.74%
Expected life of options (years) (3)	3	3.00
Forfeiture rate	9.27%	10.30%
Equity correlation against peer group (4)	39.14 %	47.51 %

(1)

The risk-free rate is based on Canada government bonds with a remaining term equal to the expected life of the PSUs.

(2)

Volatility was estimated by using the 20-day VWAP historical volatility of Aurora and the peer group of companies.

(3)

The expected life in years represents the period of time that the PSUs granted are expected to be outstanding.

(4)

The equity correlation is estimated by using 1-year historical equity correlations for the Company and the peer group of companies.

 

The weighted average fair value of PSUs granted during the three months ended June 30, 2023 was $0.76 per unit (three months ended June 30, 2022 - $4.53 per unit).

 

(d) Cash Settled DSUs and PSUs

 

On June 23, 2023, the Company issued 296,052 DSUs and 3,957,593 PSUs that will be settled in cash, pursuant to the Performance Share Unit and Restricted Share Unit Long-Term Cash Settled Plan and Non-Employee Directors Deferred Share Unit Cash Plan, respectively. The DSUs and RSUs issued under these plans are included in the continuities above.

 

The DSUs subject to cash settlement are classified as a derivative liability. They are initially measured at fair value and recorded as a derivative liability in the consolidated statements of financial position. DSUs are issued in recognition of past service for Directors and are therefore recorded at the full amount to share-based compensation expense in the consolidated statements of loss and comprehensive loss. The DSUs are remeasured each reporting period with the difference going through share-based compensation expense. Upon settlement, the DSU’s are remeasured and the derivative liability is extinguished at the remeasured amount. During the three months ended June 30, 2023, the Company recognized $0.2 million as both the derivative liability and share-based compensation expense in respect of the cash settled DSUs.

 

The PSUs subject to cash settlement are classified as a derivative liability. They are initially measured at fair value using a Monte Carlo simulation model and recorded as a derivative liability in the consolidated statements of financial position. The PSUs have a service requirement of three years and are amortized ratably over that period. The PSUs are remeasured each reporting period with the change in value reflected in the share-based compensation expense. As at June 30, 2023, the Company recognized a derivative liability for a nominal amount with an equal amount recognized as share based compensation expense in the condensed consolidated statements of loss and comprehensive loss.

  

Note 13 Loss Per Share

 

The following is a reconciliation of basic and diluted loss per share:

 

Basic and diluted loss per share

 

	Three months ended June 30, 2023	Three months ended June 30, 2022
Net loss from continuing operations attributable to Aurora shareholders	($20,771)	($617,032)
Net loss from discontinued operations attributable to Aurora shareholders	($6,127)	($1,755)
Net loss attributable to Aurora shareholders	($26,898)	($618,787)
Weighted average number of Common Shares outstanding	353,558,623	249,046,668
Basic loss per share, continuing operations	($0.06)	($2.48)
Basic loss per share, discontinued operations	($0.02)	($0.01)
Basic loss per share	($0.08)	($2.49)

 

Diluted loss per share is the same as basic loss per share as the issuance of shares on the exercise of convertible debentures, RSU, DSU, PSU, warrants and share options are anti-dilutive.

 

Note 14 Other (Losses) Gains

	Note	Three months ended June 30, 2023	Three months ended June 30, 2022
		$	$
Share of net income from investment in associates		-	51
Unrealized gain (loss) on derivative investments		388	(3,349)
Unrealized gain on derivative liability	11(c)	3,920	15,748
Unrealized loss on changes in contingent consideration fair value		(414)	(2)
Gain on disposal of assets held for sale and property, plant and equipment	5, 6	1,631	4,029
Government grant income (expense)		-	(867)
Provisions		200	(3,372)
Realized loss on repurchase of convertible debt	8	(5,941)	(18,348)
Other gain (losses)		369	(933)
Total other gains (losses)		153	(7,043)

 

Note 15 Supplemental Cash Flow Information

 

The changes in non-cash working capital are as follows:

	Three months ended June 30, 2023	Three months ended June 30, 2022
	$	$
Accounts receivable	8,242	3,801
Biological assets	(4,337)	(17,792)
Inventory	15,844	19,793
Prepaid and other current assets	(1,653)	(277)
Accounts payable and accrued liabilities	(14,825)	8,867
Income taxes payable	285	(511)
Deferred revenue	195	(471)
Provisions	-	2,213
Other current liabilities	63	(442)
Changes in operating assets and liabilities	3,814	15,181

 

Additional supplementary cash flow information is as follows:

	Three months ended June 30, 2023	Three months ended June 30, 2022
	$	$
Property, plant and equipment in accounts payable	(2,060)	(2,087)
Right-of-use asset additions	-	(359)
Amortization of prepaids	4,984	6,934
Interest paid (received)	2,416	(275)
Interest received	(863)	(199)

Included in restricted cash as of June 30, 2023 is $3.4 million (June 30, 2022 - $3.4 million) attributed to collateral held for letters of credit and

corporate credit cards, $6.0 million (June 30, 2022 - nil) related to the Bevo acquisition, $20.5 million (June 30, 2022 - $15.0 million) for self- insurance, $0.1 million (June 30, 2022 - $0.2 million) attributed to international subsidiaries, and $35.6 million (June 30, 2022 - $32.4 million) of funds reserved for the segregated cell program for insurance coverage.

 

Note 16 Commitments and Contingencies

 

(a)

Claims and Litigation

 

From time to time, the Company and/or its subsidiaries may become defendants in legal actions and the Company intends to take appropriate action with respect to any such legal actions, including by defending itself against such legal claims as necessary. Other than the claims described below, as of the date of this report, Aurora is not aware of any other material or significant claims against the Company.

 

On November 21, 2019, a purported class action proceeding was commenced in the United States District Court for the District of New Jersey against the Company and certain of its current and former directors and officers on behalf of persons or entities who purchased, or otherwise acquired, publicly traded Aurora securities between October 23, 2018 and February 6, 2020. An amended complaint was filed on September 21, 2020 which alleges, inter alia, that the Company and certain of its current and former officers and directors violated the federal securities laws by making false or misleading statements, materially overstated the demand and potential market for the Company’s consumer cannabis products; that the Company’s ability to sell products had been materially impaired by extraordinary market oversupply, that the Company’s spending growth and capital commitments were slated to exceed our revenue growth; that the Company had violated German law mandating that companies receive special permission to distribute medical products exposed to regulated irradiation techniques, and that the foregoing, among others, had negatively impacted the Company’s business, operations, and prospects and impaired the Company’s ability to achieve profitability. A motion to dismiss was filed on November 20, 2020 and granted by the court on July 7, 2021, however, the plaintiffs were given an opportunity to file a second amended complaint no later than September 7, 2021. Pursuant to the July 7, 2021 order, the plaintiffs filed a second amended complaint on September 7, 2021 which included new allegations pertaining to certain alleged financial misrepresentation and improper revenue recognition by the Company. The Company subsequently filed a motion to dismiss on December 6, 2021 and a reply to plaintiffs’ opposition on March 25, 2022. Again, on a judgement dated September 23, 2022 the Court granted the second motion to dismiss the case in favour the Company. The motion was granted without prejudice. The plaintiff’s counsels re-filed a third statement of claim on November 7, 2022 and the re-stated claim was received by Aurora formally on November 8, 2022. The Company filed a third further motion to dismiss on January 6, 2023, to which the plaintiffs have filed an opposition brief and the Company subsequently filed a reply. While this matter is ongoing, the Company disputes the allegations and intends to continue to vigorously defend against the claims. Estimating an amount or range of possible losses resulting from litigation proceedings is inherently difficult, particularly where the matters involve indeterminate claims for monetary damages and are in the stages of the proceedings where key factual and legal issues have not been resolved. For these reasons, the Company is currently unable to predict the ultimate timing or outcome of or reasonably estimate the possible losses or a range of possible losses resulting from the matters described above.

 

The Company and its subsidiary, ACE, have been named in a purported class action proceeding which commenced on June 16, 2020 in the Province of Alberta in relation to the alleged mislabeling of cannabis products with inaccurate THC/CBD content. The class action involves a number of other parties including Aleafia Health Inc., Hexo Corp, Tilray Canada Ltd., among others, and alleges that upon laboratory testing, certain cannabis products were found to have lower THC potency than the labeled amount, suggesting, among other things, that plastic containers may be leeching cannabinoids. While this matter is ongoing, the Company disputes the allegations and intends to vigorously defend against the claims. Estimating an amount or range of possible losses resulting from litigation proceedings is inherently difficult, particularly where the matters involve indeterminate claims for monetary damages and are in the stages of the proceedings where key factual and legal issues have not been resolved. For these reasons, the Company is currently unable to predict the ultimate timing or outcome of or reasonably estimate the possible losses or a range of possible losses resulting from the matter described above.

 

A claim was commenced by a party to a former term sheet on June 15, 2020 with the King's Bench of Alberta against Aurora and a former officer alleging a claim of breach of obligations under said term sheet, with the plaintiff seeking $18.0 million in damages. While this matter is ongoing, the Company believes the action to be without merit and intends to defend the claim.

 

On August 10, 2020, a purported class action lawsuit was filed with the King's Bench of Alberta against Aurora and certain executive officers in the Province of Alberta on behalf of persons or entities who purchased, or otherwise acquired, publicly traded Aurora securities and suffered losses as a result of Aurora releasing statements containing misrepresentations during the period of September 11, 2019 and December 21, 2019. Chambers appointment has been scheduled for January 2024. The Company disputes the allegations and intends to vigorously defend against the claims. Estimating an amount or range of possible losses resulting from litigation proceedings is inherently difficult, particularly where the matters involve indeterminate claims for monetary damages and are in the stages of the proceedings where key factual and legal issues have not been resolved. For these reasons, the Company is currently unable to predict the ultimate timing or outcome of or reasonably estimate the possible losses or a range of possible losses resulting from the matter described above.

 

On January 4, 2021, a civil claim was filed with the King’s Bench of Alberta against Aurora and Hempco by a former landlord regarding unpaid rent in the amount of $8.9 million, representing approximately $0.4 million for rent in arrears and costs, plus $8.5 million for loss of rent and remainder of the term. The Company filed a statement of defense on March 24, 2021. Plaintiffs were to bring a summary judgement application which is being opposed by Aurora and which application will likely not be heard until 2024. Questioning on Affidavits is scheduled to begin in the Fall of 2023. While this matter is ongoing, the Company intends to continue to defend against the claims.

 

The Company, its subsidiary ACE, and MedReleaf Corp. (which amalgamated with ACE in July 2020) have been named in a purported class action proceeding commenced on November 15, 2022 in the Ontario Superior Court of Justice. The purported class action claims that the Company failed to warn of certain risks purported to be associated with the consumption of cannabis. The Statement of Claim was served upon the Company on November 22, 2022 and a Statement of Defence was filed and served. The next major step in the process is scheduling a timetable for the remaining deliverables of the process, including delivery of the plaintiff’s certification motion record. The plaintiff must either deliver their certification materials or come to an agreement with the Aurora Defendants on a timetable for doing so within one year of commencing the proposed class action. The Court has issued an order allowing the representative plaintiff to remain anonymized in all court documents, including identifying her by “V.T”. The Company disputes the allegations and intends to defend against the claims.

 

On May 5, 2022, Aurora Cannabis Inc. acquired all issued and outstanding shares of Terrafarma Inc. Terrafarma Inc. is now a wholly owned subsidiary of Aurora Cannabis Inc. Prior to Aurora’s acquisition of Terrafarma, a former employee of Terrafarma commenced a claim for wrongful dismissal seeking damages in the amount $1,046,400 plus additional damages relating to certain options and unpaid bonus. The Company disputes the allegations and intends to defend against the claims.

 

A claim was commenced by a former employee of Aurora against Aurora Cannabis Enterprises Inc. and another former employee of Aurora (the “Defendant Employee”). The plaintiffs claim that the Defendant Employee entered a lease for a property owned by the plaintiffs in January 2017 and states that Aurora was a guarantor for the Defendant Employee. The claim states that the Defendant Employee left the property and caused damage. The plaintiffs further claim outstanding rent and legal fees. There is no record of any documentation of Aurora being a party to any such relationship. The Defendant Employee has been noted in default by the plaintiff and Aurora has filed and served a Third-Party Notice against the Defendant Employee. The Company disputes the allegations and intends to defend against the claims.

 

The Company is subject to litigation and similar claims in the ordinary course of our business, including claims related to employment, human resources, product liability and commercial disputes. The Company has received notice of, or are aware of, certain possible claims against us where the magnitude of such claims is negligible, or it is not currently possible for us to predict the outcome of such claims, possible claims or lawsuits due to various factors including: the preliminary nature of some claims; an incomplete factual record; and the unpredictable nature of opposing parties and their demands. Management is of the opinion, based upon legal assessments and information presently available, that it is unlikely that any of these claims would result in liability to the Company, to the extent not provided for through insurance or otherwise, would have a material effect on the consolidated financial statements, other than the claims described above.

 

In respect of the aforementioned claims, as at June 30, 2023 the Company has recognized total provisions of $1.0 million (March 31, 2023 - $1.0 million) in provisions on the condensed consolidated statements of financial position and a settlement accrual for nil (March 31, 2023 - $1.0 million) in accounts payable and accrued liabilities on the consolidated statements of financial position.

 

(b)

Commitments

 

The Company has various lease commitments related to various office space, production equipment, vehicles, facilities and warehouses expiring up to June 2033. The Company has certain leases with optional renewal terms that the Company may exercise at its option.

 

In addition to lease liability commitments disclosed in Note 20(b) and loans and borrowing repayments in Note 9, the Company has $1.5 million in future capital commitments and purchase commitments payments, which are due over the next 12 months.

 

Note 17 Revenue

 

The Company generates revenue from the transfer of goods and services over time and at a point-in-time from the revenue streams below. Net revenue from sale of goods is reflected net of actual returns and estimated variable consideration for future returns and price adjustments of $0.6 million for the three months ended June 30, 2023 (three months ended June 30, 2022 - $(0.5) million). The estimated variable consideration is based on historical experience and management’s expectation of future returns and price adjustments. As of June 30, 2023, the net return liability for the estimated variable revenue consideration was $1.3 million (March 31, 2023 - $1.6 million) and is included in deferred revenue on the condensed consolidated interim statements of financial position.

Three Months Ended June 30, 2023	Point-in-time	Over-time	Total
	$	$	$
Cannabis
Revenue from sale of goods	61,529	-	61,529
Revenue from provision of services	-	143	143
Excise taxes	(6,466)	-	(6,466)
Cannabis Net Revenue	55,063	143	55,206
Plant Propagation
Revenue from sale of goods	19,904	-	19,904
Net revenue	74,967	143	75,110

 

Three Months Ended June 30, 2022	Point-in-time	Over-time	Total
	$	$	$
Cannabis
Revenue from sale of goods	57,128	-	57,128
Revenue from provision of services	-	327	327
Excise taxes	(7,339)	-	(7,339)
Net revenue	49,789	327	50,116

 

Note 18 Segmented Information

 

Operating Segments	Canadian Cannabis	EU Cannabis	Plant Propagation	Corporate (1)	Total
	$	$		$	$
Three months ended June 30, 2023
Net revenue	44,819	10,387	19,904	-	75,110
Gross profit before fair value adjustments	6,990	5,760	953	-	13,703
Selling, general, and administrative expense	27,266	3,789	438	3,187	34,680
Net (loss) income before taxes and discontinued operations	(6,996)	1,506	(383)	(16,235)	(22,108)
Three months ended June 30, 2022
Net revenue	38,499	11,573	-	44	50,116
Gross profit (loss) before fair value adjustments	(2,161)	6,961	-	22	4,822
Selling, general, and administrative expense	36,952	3,841	-	5,622	46,415
Net (loss) income before taxes and discontinued operations	(521,168)	(21,704)	-	(75,512)	(618,384)

(1)

Net (loss) income under the Corporate allocation includes fair value gains and losses from investments in marketable securities, derivatives and investment in associates. Corporate and administrative expenditures such as regulatory fees, share based compensation and financing expenditures relating to debt issuances are also included under Corporate.

 

 

Geographical Segments	Canada	EU	Other	Total
	$	$	$	$
Non-current assets other than financial instruments
June 30, 2023	364,084	37,937	-	402,021
March 31, 2023	375,179	41,866	105	417,150
Three months ended June 30, 2023
Net revenue	64,346	10,387	377	75,110
Gross profit (loss) before fair value adjustments	8,928	5,760	(985)	13,703
Three months ended June 30, 2022
Net revenue	38,965	11,723	(572)	50,116
Gross profit (loss) before fair value adjustments	(1,385)	7,087	(880)	4,822

 

Included in net revenue for the three months ended June 30, 2023 are net revenues of approximately $14 million from Customer G (three months ended June 30, 2022 - Customer A - $5 million), each contributing 10% or more to the Company’s net revenue.

 

Note 19 Fair Value of Financial Instruments

 

The carrying values of the financial instruments at June 30, 2023 are summarized in the following table:

	Amortized cost	FVTPL	Designated FVTOCI	Total
	$	$	$	$
Financial Assets
Cash and cash equivalents	157,855	-	-	157,855
Restricted cash	65,655	-	-	65,655
Accounts receivable, excluding sales taxes and lease receivable	30,095	-	-	30,095
Derivative assets	-	7,422	-	7,422
Lease receivable	10,481	-	-	10,481
Financial Liabilities
Accounts payable and accrued liabilities	62,482	-	-	62,482
Convertible debentures	65,107	-	-	65,107
Contingent consideration payable	-	12,964	-	12,964
Other current liabilities	12,635	-	-	12,635
Lease liabilities	46,727	-	-	46,727
Derivative liabilities	-	5,945	-	5,945
Loans and borrowings	44,550	-	-	44,550
Other long-term liabilities	50,230	-	-	50,230

.

The following is a summary of financial instruments measured at fair value segregated based on the various levels of inputs:

	Notes	Level 1	Level 2	Level 3	Total
		$	$	$	$
As at June 30, 2023
Derivative assets		-	7,422	-	7,422
Contingent consideration payable		-	-	12,964	12,964
Derivative liabilities	8, 11(c), 12(d)	5,945	-	-	5,945
As at March 31, 2023
Derivative assets		-	7,114	135	7,249
Contingent consideration payable		-	-	12,487	12,487
Derivative liabilities	8, 11(c), 12(d)	9,634	-	-	9,634

 

There have been no transfers between fair value categories during the period.

 

Note 20 Financial Instruments Risk

 

The Company is exposed to a variety of financial instrument related risks. The Board mitigates these risks by assessing, monitoring and approving the Company’s risk management processes.

 

(a)

Credit risk

 

Credit risk is the risk of a potential loss to the Company if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company is moderately exposed to credit risk from its cash and cash equivalents, accounts receivable and loans receivable. The risk exposure is limited to their carrying amounts reflected on the consolidated statements of financial position. The risk for cash and cash equivalents is mitigated by holding these instruments with highly rated Canadian financial institutions. Certain restricted funds in the amount of are retained by an insurer under the Segregated Accounts Companies Act governed by the Bermuda Monetary Authority. As the Company does not invest in asset-backed deposits or investments, it does not expect any credit losses. The Company periodically assesses the quality of its investments and is satisfied with the credit rating of the financial institutions and the investment grade of its Guaranteed Investment Certificates (“GICs”). The Company mitigates the credit risk associated with the loans receivable by managing and monitoring the underlying business relationship.

 

The Company provides credit to certain customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Credit risk is generally limited for receivables from government bodies, which generally have low default risk. Credit risk for non-government wholesale customers is assessed on a case-by-case basis and a provision is recorded where required. As of June 30, 2023, $20.4 million of accounts receivable, net of allowances, are from non-government wholesale customers (March 31, 2023 - $20.9 million). As of June 30, 2023, the Company recognized a $1.6 million provision for expected credit losses (March 31, 2023 - $3.4 million).

 

The Company’s aging of trade receivables, net was as follows:

	June 30, 2023	March 31, 2023
	$	$
0 - 60 days	23,571	28,355
61+ days	6,265	6,661
	29,836	35,016

 

The Company’s contractual cash flows from lease receivables is as follows:

 

		June 30, 2023
		$
Next 12 months		2,861
Over 1 year to 2 years		2,666
Over 2 years to 3 years		1,984
Over 3 years to 4 years		1,919
Over 4 years to 5 years		1,409
Thereafter		1,256
Total undiscounted lease payments receivable		12,095
Unearned finance income		(1,614)
Total lease receivable		10,481
Current		(2,341)
Long-term		8,140

 

(b)

Liquidity risk

 

The composition of the Company’s accounts payable and accrued liabilities was as follows:

	June 30, 2023	March 31, 2023
	$	$
Trade payables	13,776	21,942
Accrued liabilities	28,414	38,176
Payroll liabilities	17,766	12,610
Excise tax payable	2,131	2,611
Other payables	395	486
	62,482	75,825

 

In addition to the commitments outlined in Note 16, the Company has the following undiscounted contractual obligations as at June 30, 2023, which are expected to be payable in the following respective periods:

	Total	≤1 year	Over 1 year - 3 years	Over 3 years - 5 years	> 5 years
	$	$	$	$	$
Accounts payable and accrued liabilities	62,482	62,482	-	-	-
Convertible notes and interest (1)	70,006	70,006	-	-	-
Lease liabilities (2)	97,034	8,244	21,223	14,350	53,217
Loans and borrowings	44,550	9,439	2,639	6,766	25,706
Contingent consideration payable (3)	12,964	2,610	10,354	-	-
	287,036	152,781	34,216	21,116	78,923

(1)

Assumes the principal balance of the debentures outstanding at June 30, 2023 remains unconverted and includes the estimated interest payable until the maturity date.

(2)

Includes interest payable until maturity date.

(3)

Relates to acquired businesses. Payable in cash, shares, or a combination of both at Aurora’s sole discretion.

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with its financial liabilities when they are due. The Company manages liquidity risk through the management of its capital structure and resources to ensure that it has sufficient liquidity to settle obligations and liabilities when they are due. Our ability to fund our operating requirements depends on future operating performance and cash flows, which are subject to economic, financial, competitive, business and regulatory conditions, and other factors, some of which are beyond our control. Our primary short-term liquidity needs are to fund our net operating losses, capital expenditures to maintain existing facilities, convertible debenture repayment and lease payments. Our medium-term liquidity needs primarily relate lease payments and our long-term liquidity needs primarily relate to potential strategic plans.

 

As of June 30, 2023, the Company has access to the following capital resources available to fund operations and obligations:

 

•

$157.9 million cash and cash equivalents; and

•

access to the 2023 Shelf Prospectus (as defined below). The Company currently has access to securities registered for sale under the 2023 Shelf Prospectus currently covering US$650.0 million of issuable securities. Of the U.S.$650 million of securities registered under the 2023 Shelf Prospectus and corresponding registration statement on form F-10 filed with the U.S. Securities and Exchange Commission in the U.S., approximately U.S.$409 million is allocated to the potential exercise of currently outstanding warrants issued in financing transactions from 2020 to 2022. As a result, approximately U.S.$241 million is available for potential new issuances of Common Shares, warrants, options, subscription receipts, debt securities or any combination thereof during the 25-month period that the 2023 Shelf Prospectus remains effective. Volatility in the cannabis industry, stock market and the Company’s share price may impact the amount and our ability to raise financing under the 2023 Shelf Prospectus.

 

Based on all of the aforementioned factors, the Company believes that its reduction of operating costs, current liquidity position, and access to the 2023 Shelf Prospectus are adequate to fund operating activities and cash commitments for investing, financing and strategic activities for the foreseeable future. In addition, the Company could access restricted cash of $20.5 million relating to its self insurance policy, if necessary.

 

Note 21 Subsequent Events

 

Subsequent to June 30, 2023, the Company repurchased approximately $6.6 million (U.S$5.0 million) aggregate principal amount of convertible senior notes at a 1.5% average discount to par value, with the issuance of 10,274,950 Common Shares.

 

 

29

 

Exhibit 99.2

 

 

 

 

 

 

 

 

AURORA CANNABIS INC.

 

Management’s Discussion & Analysis

 

 

 

For the three months ended June 30, 2023 and 2022

(in Canadian Dollars)

Management’s Discussion & Analysis

Table of Contents

Business Overview	3
Condensed Statement of Comprehensive Loss	5
Key Quarterly Financial and Operating Results	6
Key Developments During and Subsequent to Three Months Ended June 30, 2023	6
Financial Review	7
Liquidity and Capital Resources	14
Related Party Transactions	17
Critical Accounting Estimates	18
Change in Accounting Policies	18
Recent Accounting Pronouncements	19
Financial Instruments	19
Financial Instruments Risk	20
Summary of Outstanding Share Data	21
Historical Quarterly Results	22
Risk Factors	22
Internal Controls Over Financial Reporting	24
Cautionary Statement Regarding Forward-Looking Statements	25
Cautionary Statement Regarding Certain Non-GAAP Performance Measures	26

 

 

Interim Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended June 30, 2023

 

The following Interim Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) of Aurora Cannabis Inc. (“Aurora” or the “Company”) should be read in conjunction with both the Company’s annual audited consolidated financial statements as at and for the year ended March 31, 2023 (the “Annual Financial Statements”), and the condensed consolidated interim financial statements as at and for the three months ended June 30, 2023 and the accompanying notes thereto (the “Financial Statements”), which have been prepared in accordance with International Accounting Standards 34 - Interim Financial Reporting (“IAS 34”) of International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board. The MD&A has been prepared as of August 9, 2023 pursuant to the disclosure requirements under National Instrument 51-102 - Continuous Disclosure Obligations (“NI 51-102”) of the Canadian Securities Administrators (“CSA”). Under the United States (“U.S.”) / Canada Multijurisdictional Disclosure System, we are permitted to prepare the MD&A in accordance with Canadian disclosure requirements which may differ from U.S. disclosure requirements.

 

In 2022, the Company announced a change to its fiscal year end from June 30 to March 31. The Company filed a notice of change of year end

on February 24, 2023 pursuant to Part 4 of NI 52-102. Consequently, the Company reported annual financial results for a nine-month transition period from July 1, 2022 to March 31, 2023. References to “fiscal 2024” or “FY 2024” are in respect of the twelve months ended March 31, 2024 and references to “fiscal 2023” or “FY 2023” are in respect of the nine months ended March 31, 2023.

 

Given the Company’s change in year-end and recent business transformation initiatives to realign its operational footprint and increase financial flexibility, this MD&A provides comparative disclosures for the first quarter ended June 30, 2023 (“Q1 2024”) to the fourth quarter of fiscal 2022 ended June 30, 2022 (“Q4 2022”) and to the third quarter of fiscal 2023 ended March 31, 2023 (“Q3 2023”). Management believes that these comparatives provide relevant and current information.

 

All dollar amounts are expressed in thousands of Canadian dollars, except for share and per share amounts, and where otherwise indicated.

 

This MD&A contains forward-looking information within the meaning of applicable securities laws, and the use of Non-GAAP Measures (as defined below). Refer to “Cautionary Statement Regarding Forward-Looking Statements” and “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” included within this MD&A.

 

This MD&A, Financial Statements, and Annual Financial Statements, annual information form (“AIF”) and press releases have been filed in Canada on SEDAR at www.sedar.com and in the U.S. on EDGAR at www.sec.gov/edgar. Additional information can also be found on the Company’s website at www.auroramj.com.

 

Business Overview

 

Aurora was incorporated under the Business Corporations Act (British Columbia) on December 21, 2006 as “Milk Capital Corp.” Effective October 2, 2014, the Company changed its name to “Aurora Cannabis Inc.”. The Company’s shares are listed on the Nasdaq Global Select Market (“Nasdaq”) and the Toronto Stock Exchange (“TSX”) under the trading symbol “ACB”, and on the Frankfurt Stock Exchange (“FSE”) under the trading symbol “21P”.

 

The Company’s head office and principal address is 3498 - 63 Avenue, Leduc, Alberta, Canada, T9E 0G8. The Company’s registered and records office address is Suite 1700, 666 Burrard Street, Vancouver, British Columbia Canada, V6C 2X8.

 

The Company’s principal strategic business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally, and the propagation of vegetables and ornamental plants.

 

The Company’s primary cannabis market opportunities are:

 

•

Global medical cannabis market: Production, distribution and sale of pharmaceutical-grade cannabis products in countries around the world where permitted by government legislation. Currently, there are approximately 50 countries that have implemented regimes for some form of access to cannabis for medical purposes. The Company’s current principal medical markets are in Canada, Germany, UK, Poland, and Australia. Aurora has established a leading market position in most of these countries; and

 

•

Global consumer use cannabis market: Currently, only Canada and Uruguay have implemented federally-regulated consumer use of cannabis regimes and the Company has primarily focused on the opportunities in Canada. Longer-term, the Company believes that the increasing success of medical cannabis regimes globally may lead to increased legalization of consumer markets.

 

On August 25, 2022, a wholly-owned subsidiary of the Company acquired a 50.1% controlling interest in Bevo Agtech Inc. (“Bevo”), the sole parent of Bevo Farms Ltd., one of the largest suppliers of propagated vegetables and ornamental plants in North America. The acquisition of a controlling interest in Bevo allows the Company to immediately benefit from a profitable, cash flow positive and growing business, and may have the potential to add long term value to Aurora's existing cannabis business via the application of Bevo's industry extensive propagation expertise.

 

Our Strategy

 

Aurora’s strategy is to leverage our diversified and scaled platform, our leadership in global medical markets, and our cultivation, science and genetics expertise and capabilities to drive profitability and cash flow in our core Canadian and international operations in order to build sustainable, long-term shareholder value.

 

 

 

Medical leadership

 

Our established leadership in the Canadian and International medical markets positions us well for new regulated medical market openings, as well as potential U.S. federal legalization of medical cannabis. At the core of Aurora’s mid-term objective to deliver sustainable profitability and positive operating cash flow is our focus on maintaining and growing our industry leading Canadian and international medical cannabis operations.

 

Our Canadian medical platform is characterized by leading market share, high barriers to entry through regulatory expertise, investment in technology and distribution, and unwavering commitment to science, testing and compliance. Our Canadian medical operations allow for a direct-to-patient sales channel that does not rely on provincial wholesalers or private retailers to get product to patients. This direct-to-patient model allows Aurora to achieve sustainable gross profit margins of better than 60% with substantially better pricing power relative to the Canadian adult-use segment.

 

Our leadership in the International medical cannabis segment provides us with what we expect to be a high growth, profitable business segment that consistently delivers strong adjusted gross profit before fair value adjustments¹. Our expertise in managing the complexity of multiple jurisdictions’ regulatory frameworks and relationships, as well as providing export and in-country EU GMP (European Union Good Manufacturing Practices) and other key certificated cannabis production, are capabilities that we believe will us to succeed as new medical and recreational markets open.

 

Consumer

 

Leveraging our leading strength in science, cultivation and post-harvest processing, Aurora is building a profitable and growing Canadian consumer business. Advances in Aurora production related to cultivar breeding, cultivation, and post-harvest techniques have repositioned the Aurora flower portfolio to one that has the characteristics that consumers are looking for: high THC and terpene levels, and distinctive experiences. These advances have also driven significant improvement in per unit production costs with higher yields and consistent delivery of specification resulting in all-in per unit costs for Aurora’s new portfolio that are 30% or better improvement from our legacy cultivars. We believe this economic advantage will allow us to compete and make a profit in certain categories in which we currently do not operate. We have also refocused our innovation pipeline for efficient delivery of targeted new products and line extensions. The pace of innovation required to compete in the current Canadian consumer market is significant, with most new products delivering 80% of their lifetime value in the six to nine months following launch.

 

Combined, Aurora’s ability to deliver products that deliver exceptional customer value in all price tiers, while at the same time achieving strong contribution and gross margins, allows us to build towards a profitable and growing business and provides the know-how to leverage these lessons into future global consumer markets that are expected to open over the next few years.

 

Science leadership: Genetics, Breeding, Biosynthetics

 

We believe that our scientific leadership and ongoing investment in cannabis breeding and genetics provides Aurora with a strong competitive advantage in premium margin consumer and medical categories driven by what we believe to be our industry leading genetics and breeding program. Our breeding program, located at Aurora Coast, a state-of-the-art facility in Vancouver Island’s Comox Valley, is driving revenues by injecting rotation and variety into our product pipeline and has delivered seventeen new proprietary cultivars to our product pipeline since June 2021. These new cultivars have consistently delivered high potency flower with intensely aromatic profiles - critical attributes to delight consumers and deliver the effects patients are seeking. Cultivars like Farm Gas and Sourdough - launched in Canada in spring 2022, are now available to patients globally. These have now been launched in Europe and Australia and provide patients with some of the highest potency and most appealing offerings in those markets. Domestically, Aurora’s latest launches include Pink Diesel ’71, which averages at 27.6% THC, and Moon Berry, which is a novel 1:1 offering patients and consumers with a lower potency, more “sessionable” offering. Both cultivars, along with other new launches, Chemango Kush and Ponderosa Pine, are available now in our Canadian Consumer and Medical channels.

 

In addition, high quality and high potency cultivars that also deliver meaningful improvements in yield are setting Aurora up for long-term success with lower per gram cultivation costs. In selecting Aurora’s “next-generation” cultivars, we are able to set substantially higher minimum thresholds for yield which continue to drive up our overall production using the same cultivation footprint, improving our cultivation efficiency over time. This improvement allows us to produce top quality flower at industry leading margins. Our pipeline is now full at every stage of the breeding and selection cycle, and Aurora plans to continue to introduce new cultivars including new high THC, intensely aromatic flower, and new balanced cultivars.

 

Global and U.S. expansion

 

We believe that the global expansion of cannabis medical and recreational markets is just beginning. The Company believes its strengths in navigating complex regulatory environments, compliance, testing, cultivar breeding, genetic science, and cultivating high quality cannabis are essential strengths that create a repeatable, credible and portable process to new market development. These drive our current leadership in international medical markets which should allow us to win as new medical markets emerge and potentially transition to recreational markets. For instance, Aurora and its partner won three of nine awarded tenders, representing all of the available dry flower tenders, in the French medical cannabis trial program, a large medical market expected to open fully in the next two years. In addition, Aurora is at the forefront of large developing federally legal consumer markets, with a leading position in the German medical market and as one of three domestic German producers, is well positioned as that country’s government works toward introducing consumer market legislation as early as 2025.

 

We also believe that the U.S. cannabis market will eventually be federally regulated, with states’ rights respected, in a framework similar to every other comparable market. The timeframe for this is unknown, but Aurora is well positioned to create significant value for our shareholders once that federal permissibility allows. Our strategic strengths of medical and regulatory expertise in a federal framework, and our scientific expertise, including genetics, breeding, and biosynthetics, position us as a partner of choice, and to be successful in lucrative components of the cannabis value chain.

 

¹Adjusted gross margin before fair value is a Non-GAAP Measure and is defined in the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A. Refer to the “Adjusted Gross Margin” section for a reconciliation to IFRS equivalent.

 

 

 

Plant Propagation

 

With the acquisition of Bevo in August 2022, Aurora moved into an adjacent segment of plant propagation. Building on the established record of profitable and positive cash flow, Aurora is accelerating the growth of plant propagation through the repurposing of Aurora Sky and Aurora Sun, which will open additional geographic regions for the existing propagation business, as well as allowing entry into the higher gross margin orchid business, one which is currently served in North America by lower-quality imports.

 

Financial leadership in a rapidly maturing industry

 

Aurora believes that profitable growth, positive cash flow, smart capital allocation and balance sheet health are critical success factors in such a dynamic and rapidly developing global industry. Our medical businesses, with country diversification, growth, and strong gross margins provide the foundation for profitability. Aurora has right sized selling, general & administration costs (“SG&A”), centralized and optimized production facilities, and leveraged the Company’s cultivar breeding success to shift the Company’s portfolio in the Canadian consumer business to products with higher gross margins.

 

Aurora has one of the strongest balance sheets in the Canadian cannabis industry with approximately $214.2 million of cash on hand as of July 31, 2023 and access to a shelf prospectus filed on April 27, 2023 (the “2023 Shelf Prospectus”) currently covering US$650.0 million of issuable securities. Of the U.S.$650 million of securities registered under the 2023 Shelf Prospectus and corresponding registration statement on form F-10 filed with the U.S. Securities and Exchange Commission in the U.S., approximately U.S.$409 million is allocated to the potential exercise of currently outstanding warrants issued in financing transactions from 2020 to 2022. As a result, approximately U.S.$241 million is available for potential new issuances of Common Shares, warrants, options, subscription receipts, debt securities or any combination thereof during the 25-month period that the 2023 Shelf Prospectus remains effective. Volatility in the cannabis industry, stock market and the Company’s share price may impact the amount and our ability to raise financing under the 2023 Shelf Prospectus.

 

Cash flow continues to improve with a reduction in cash used in operations. Excluding changes in non-cash working capital², cash used in operating activities during the three months ended June 30, 2023 was $14.8 million compared to $37.5 million during the three months ended June 30, 2022, and minimal levels of capital expenditures. The Company’s plan to reduce costs by a further $40 million annualized before the end of fiscal 2024 is expected to continue to improve operating cash use over the next several quarters and support the Company’s initiative to achieve positive free cash flow during calendar year 2024.

 

Condensed Statements of Loss

 

The consolidated statements of loss and comprehensive loss and consolidated statements of cash flows for the previously reported Growery and Nordic, formerly part of the EU Cannabis operating segment are presented as discontinued operations, separate from the Company’s continuing operations. Certain prior period financial information on the consolidated statements of loss and comprehensive loss and the consolidated statements of cash flows have been updated to present Growery and Nordic as a discontinued operations, and has therefore been excluded from both continuing operations and results for all periods presented in this MD&A. This MD&A reflects only the results of continuing operations, unless otherwise noted.

 

The loss from discontinued operations included in the consolidated statement of loss and comprehensive loss was $6.1 million for the three months ended June 30, 2023 compared to a loss from discontinued operations of $1.8 million for the three months ended June 30, 2022.

 

	Three months ended
($ thousands)	June 30, 2023	March 31, 2023(2)	June 30, 2022(2)
Net revenue (1a)	$75,110	$64,043	$50,116
Gross profit (loss) before FV adjustments (1b)	$13,703	$20,698	$4,822
Gross profit	$25,035	$18,531	$7,130
Operating expenses	$41,149	$50,370	$67,214
Loss from operations	($16,114)	($31,839)	($60,084)
Other income (expense)	($5,994)	($48,154)	($558,300)
Net loss from continuing operations	($22,204)	($76,884)	($617,021)
Net loss from discontinuing operations, net of taxes	(6,127)	(10,341)	(1,755)
Net loss	($28,331)	($87,225)	($618,776)

(1)

These terms are defined in the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A. Refer to the following sections for reconciliation of Non-GAAP Measures to the IFRS equivalent measure:

a.

Refer to the “Cost of Sales and Gross Margin” section for a reconciliation of net revenue to the IFRS equivalent.

b.

Refer to the “Adjusted Gross Margin” section for reconciliation to the IFRS equivalent..

⁽²⁾ Comparative information has been re-presented due to discontinued operations.

 

 

 

 

² “Working Capital” is a Non-GAAP Measure and is not recognized, defined or standardized measure under IFRS. Refer to the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A

 

 

 

 

 

Key Quarterly Financial and Operating Results

 

($ thousands, except Operational Results)	Three months ended
	June 30, 2023	June 30, 2022(6)	$ Change	% Change	March 31, 2023(6)	$ Change	% Change
Financial Results
Total net revenue (1)(2a)	$75,110	$50,116	$24,994	50%	$64,043	$11,067	17%
Medical cannabis net revenue (1)(2a)	$41,615	$36,471	$5,144	14%	$38,003	$3,612	10%
Consumer cannabis net revenue (1)(2a)	$13,220	$12,638	$582	5%	$14,491	($1,271)	(9%)
Plant propagation net revenue (1)(2a)	$19,904	$ -	$19,904	100%	$10,754	$9,150	85%
Adjusted gross margin before FV adjustments on total net revenue (2b)	44%	50%	N/A	(6%)	48%	N/A	(4%)
Adjusted gross margin before FV adjustments on core cannabis net revenue (2b)	53%	56%	N/A	(3%)	51%	N/A	2%
Adjusted gross margin before FV adjustments on medical cannabis net revenue (2b)	61%	67%	N/A	(6%)	61%	N/A	0%
Adjusted gross margin before FV adjustments on consumer cannabis net revenue (2b)	27%	26%	N/A	1%	25%	N/A	2%
Adjusted gross margin before FV adjustments on plant propagation net revenue (2b)	22%	- %	N/A	22%	36%	N/A	(14%)
Adjusted SG&A expense(2d)(5)	$29,480	$34,839	($5,359)	(15%)	$27,902	$1,578	6%
Adjusted R&D expense(2d)	$1,101	$1,991	($890)	(45%)	$1,549	($448)	(29%)
Adjusted EBITDA (2c)(5)	$2,155	($8,757)	$10,912	125%	$1,254	$901	72%
Balance Sheet
Working capital (2e,f)	$227,312	$614,264	($386,952)	(63%)	$237,622	($10,310)	(4) %
Cannabis inventory and biological assets (3)	$100,846	$127,836	($26,990)	(21%)	$93,081	$7,765	8 %
Total assets	$832,188	$1,084,356	($252,168)	(23%)	$926,322	($94,134)	(10) %
Operational Results - Cannabis
Average net selling price of dried cannabis excluding bulk sales (2g)	$4.81	$5.09	($0.28)	(6%)	$4.76	$0.05	1 %
Kilograms sold (4)	15,682	13,130	2,552	19%	16,578	(896)	(5) %

(1)

Includes the impact of actual and expected product returns and price adjustments (Q1 2024 - $0.6 million; Q3 2023 - $0.3 million; Q4 2022 - $1.8 million).

(2)

These terms are defined in the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A. Refer to the following sections for reconciliation of Non-GAAP Measures to the IFRS equivalent measure:

a.

Refer to the “Revenue” and “Cost of Sales and Gross Margin” section for a reconciliation of cannabis net revenue to the IFRS equivalent.

b.

Refer to the “Adjusted Gross Margin” section for reconciliation to the IFRS equivalent.

c.

Refer to the “Adjusted EBITDA” section for reconciliation to the IFRS equivalent.

d.

Refer to the “Operating Expenses” section for reconciliation to the IFRS equivalent.

e.

“Working capital” is defined as Current Assets less Current Liabilities as reported on the Company’s Consolidated Statements of Financial Position.

f.

Current liabilities includes the current portion of convertible debentures. As at March 31, 2023, the remaining balance of convertible debentures outstanding is included in current liabilities.

g.

Net selling price of dried cannabis excluding bulk sales is comprised of revenue from dried cannabis excluding bulk sales (Q1 2024 - $39.6 million; Q3 2023 - $37.2 million; Q4 2022 - $39.0 million) less excise taxes on dried cannabis revenue excluding bulk sales (Q1 2024 - $4.2 million; Q3 2023 - $4.5 million; Q4 2022 - $5.1 million).

(3)

Represents total biological assets and inventory, exclusive of merchandise, accessories, supplies, consumables and plant propagation biological assets.

(4)

The kilograms sold, net of returns during the period.

(5)

Prior period comparatives were recast to include the adjustments for markets under development, business transformation costs, and non-recurring charges related to non-core bulk cannabis wholesales to be comparable to the current period presentation.

(6)

Comparative information has been re-presented due to discontinued operations.

 

Key Developments During and Subsequent to the Three Months Ended June 30, 2023

 

Financing Activities

 

Convertible Debt Buy Back

 

During the three months ended June 30, 2023, the Company repurchased approximately $76.9 million (U.S$57.0 million) aggregate principal amount of convertible senior notes, at a 2.3% average discount to par value, for aggregate cash consideration of approximately $61.9 million (U.S$46.0 million) and the issuance of 18,691,770 Common Shares.

 

Subsequent to June 30, 2023, the Company repurchased approximately $6.6 million (U.S$5.0 million) aggregate principal amount of convertible senior notes at a 1.5% average discount to par value, with the issuance of 10,274,950 Common Shares.

 

Aurora may, from time to time and subject to market conditions, repurchase its convertible notes, including in open market purchases and privately negotiated transactions.

 

 

 

Credit Facility

 

On August 25, 2022, through the acquisition of Bevo, the Company acquired term loans under Bevo’s credit facility (the “Credit Agreement”)

 

On April 11, 2023, the Credit Agreement was amended to reduce the term loan by $9.7 million to $38.1 million and increase the revolver by $4.0 million to $12.0 million.

 

Operating Activities

 

The Company continues to focus on growth opportunities that are also expected to deliver profit and positive cash flow:

 

•

On May 24, 2023, the Company formally made the decision to close its Aurora Nordic facility, located in Denmark due to a number of operational and regulatory challenges. The financial results of Aurora Nordic have been classified as discontinued operations. Refer to Condensed Statements of Loss section above.

 

•

On June 13, 2023, the Company formally made a decision to sell a European R&D facility, due to regulatory and financial uncertainty and other commercial factors.

 

•

On June 13, 2023, the Company formally made the decision to exit the agreement with Growery, one of the license holders entitled to participate in the Netherlands’ still-pending Controlled Cannabis Supply Chain Experiment, in order to focus on other international growth priorities. Upon completion, the Company will not have any material commercial interests in the Netherlands going forward. The financial results of Growery have been classified as discontinued operations. Refer to Condensed Statements of Loss section above.

 

•

On August 9, 2023, the Company formally made the decision to wind down its Reliva operations, based on recent pronouncements by the U.S. Food Drug Administration (“FDA”) regarding potential CBD regulation pathways and timelines. Aurora recognized an inventory impairment charge of $0.8 million during the current quarter and does not expect to incur any additional expenses in connection with the wind down.

 

Financial Review

 

Net Revenue

 

The Company primarily operates in the cannabis market. The table below outlines the revenue attributed to medical, consumer and bulk sales channels for the three months ended June 30, 2023 and the comparative periods.

 

($ thousands)	Three months ended
	June 30, 2023	March 31, 2023 (3)	June 30, 2022(3)
Medical cannabis net revenue(1)
Canadian medical cannabis net revenue	25,440	24,180	24,893
Total international medical cannabis net revenue	16,175	13,823	11,578
Total medical cannabis net revenue	41,615	38,003	36,471
Consumer cannabis net revenue(1)
Consumer cannabis net revenue	14,040	14,750	14,397
Consumer cannabis net revenue provisions	(820)	(259)	(1,759)
Total consumer cannabis net revenue	13,220	14,491	12,638
Wholesale bulk cannabis net revenue(1)
Core wholesale bulk cannabis net revenue	47	307	-
Non-core wholesale bulk cannabis net revenue	324	488	1,007
Wholesale bulk cannabis net revenue	371	795	1,007
Total cannabis net revenue	55,206	53,289	50,116
		-	-
Plant propagation revenue(2)	19,904	10,754	-
Total net revenue	75,110	64,043	50,116

(1)

Net revenue is a Non-GAAP Measure and is defined in the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A. Refer to the “Cost of Sales and Gross Margin” section of this MD&A for a reconciliation to IFRS equivalent.

(2)

Comprised of revenue from Bevo. Revenue for fiscal 2023 reflects the period from August 26, 2022 to March 31, 2023.

(3)

Comparative information has been re-presented due to discontinued operations.

 

 

 

 

 

Medical Cannabis Net Revenue

 

During the three months ended June 30, 2023, medical cannabis net revenue was $41.6 million as compared to the three months ended March 31, 2023 of $38.0 million, and $36.5 million during the three months ended June 30, 2022, representing increases of $3.6 million and $5.1 million, respectively.

 

The Company’s Canadian medical cannabis net revenue was $25.4 million during the three months ended June 30, 2023 as compared to $24.2 million during the three months ended March 31, 2023, and $24.9 million during three months ended June 30, 2022. The sequential increase of $1.3 million was due primarily to increased sales to insured patient groups. The slight increase of $0.5 million as compared to the same period in the prior year is due primarily to product sales mix, as the Company continues to innovate its product portfolio. The Company continues to focus its Canadian medical cannabis business on serving the high-margin, low-elasticity insured patient groups, representing approximately 82% of the Company’s Canadian medical cannabis net revenue during the three months ended June 30, 2023 (three months ended March 31, 2023 - 82%- ; three months ended June 30, 2022 - 79%).

 

Aurora’s International medical cannabis net revenue was $16.2 million during the three months ended June 30, 2023, as compared to $13.8 million during the three months ended March 31, 2023. The increase of $2.4 million was mainly seen in our European markets which benefited from the introduction of new cultivars. Compared against the same period in the prior year of $11.6 million, the increase of $4.6 million was largely due to a temporary situation of limited supply on high-demand cultivars in certain EU markets in the prior period. In addition, higher volumes were sold to Australia, a key export market to the Company during the current quarter compared to the prior period.

 

Consumer Cannabis Net Revenue

 

During the three months ended June 30, 2023, consumer cannabis net revenue was $13.2 million, as compared to the prior quarter of $14.5 million, and $12.6 million in the same period of the prior year. The decrease from the prior quarter of $1.3 million was due to the Company’s halt of its popular Glitches product following direction from Health Canada. The underlying consumer business, removing the impact of Glitches, grew over the prior quarter. The increase of $0.6 million from the same period in the prior year was due primarily to the release of new and innovative extract products and from the Thrive acquisition completed during the three months ended June 30, 2022.

 

Wholesale Bulk Cannabis Net Revenue

 

During the three months ended June 30, 2023, total wholesale bulk cannabis net revenue was $0.4 million as compared to $0.8 million for the three months ended March 31, 2023 and $1.0 million during the three months ended June 30, 2022.

 

As the Company’s cultivation supply is now fully allocated to sales markets, the Company did not recognize any significant sales of core wholesale bulk cannabis net revenues during the three months ended June 30, 2023. In addition, while the Company continues to opportunistically sell previous excess aged and lower potency bulk cannabis into the non-core bulk cannabis segment of the wholesale bulk cannabis channel, it is expected that these sales will continue to be insignificant as the Company’s production footprint rationalization was completed and current production is aligned with sales demand.

 

Plant Propagation Revenue

 

During the three months ended June 30, 2023, the Company’s plant propagation revenue was comprised wholly from the Bevo business, contributing $19.9 million of revenue, representing an increase of $9.2 million from the prior quarter. The increase is due to the seasonality of the Bevo business which delivers higher revenue in the late winter and spring months as orders are fulfilled. Historically, approximately 65-75% of plant propagation revenue and up to 80% of EBITDA has been earned in the first half of the calendar year.

 

Cost of Sales and Gross Margin

	Three months ended
($ thousands)	June 30, 2023	March 31, 2023	June 30, 2022
Revenue from sale of goods	81,433	70,976	57,128
Revenue from provision of services	143	213	327
Excise taxes	(6,466)	(7,146)	(7,339)
Net revenue (1)	75,110	64,043	50,116
Cost of sales	(61,407)	(43,345)	(45,294)
Gross profit before FV adjustments (1)	13,703	20,698	4,822
Gross margin before FV adjustments (1)	18%	32%	10%
Changes in fair value of inventory sold	(17,541)	(8,747)	(22,349)
Unrealized gain on changes in fair value of biological assets	28,873	6,580	24,657
Gross profit (loss)	25,035	18,531	7,130
Gross margin	33%	29%	14%

(1)

These terms are Non-GAAP Measures and neither is a recognized, defined or standardized measure under IFRS. Refer to the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A.

(2)

Comparative information has been re-presented due to discontinued operations.

 

 

Gross margin before fair value adjustments was 18% during the three months ended June 30, 2023 as compared to 32% during the three months ended March 31, 2023 and 10% during the three months ended June 30, 2022. The decrease as compared to the three months ended March 31, 2023 is mainly driven by a higher mix of plant propagation revenues and cost of goods sold during the three months ended June 30, 2023, which averages lower margins than the Company’s core cannabis business. The increase as compared to the three months ended June 30, 2022 is mainly driven by lower net inventory impairments, provisions, and destruction charges on cannabis inventory as the Company’s supply is being fully allocated to sales channels with no excess production.

 

During the three months ended June 30, 2023, gross margin was $25.0 million as compared to a gross profit of $18.5 million during the three months ended March 31, 2023 and $7.1 million during the three months ended June 30, 2022 representing an increase of $6.5 million and $17.9 million respectively. The increase as compared to the three months ended March 31, 2023 was primarily driven by increases to unrealized gains on changes in fair value of biological assets from the allocation of domestic production to higher selling price markets in the EU and higher actual yields as compared to prior quarter estimated yields. The increase to unrealized gains on changes in fair value of biological assets was partially offset with higher fair value changes in inventory sold as biological assets are harvested into inventory. The increase as compared to the three months ended June 30, 2022 is largely due to the Company’s supply now being fully allocated to sales channels with no excess production, therefore incurring lower provisions, destruction, and net realizable value impairments to inventory.

 

 

Adjusted Gross Margin - Q1 2024

 

The table below outlines adjusted gross profit and margin before fair value adjustments for the indicated three month periods.

($ thousands)	Medical Cannabis	Consumer Cannabis	Core Wholesale Bulk Cannabis	Total Core Cannabis	Non-Core Wholesale Bulk Cannabis	Plant Propagation	Total
Three months ended June 30, 2023
Gross revenue	43,872	17,429	47	61,348	324	19,904	81,576
Excise taxes	(2,257)	(4,209)	-	(6,466)	-	-	(6,466)
Net revenue (1)	41,615	13,220	47	54,882	324	19,904	75,110
Non-recurring net revenue adjustments (4)	(598)	(249)	-	(847)	-	-	(847)
Adjusted net revenue	41,017	12,971	47	54,035	324	19,904	74,263
Cost of sales	(24,547)	(17,053)	(70)	(41,670)	(752)	(18,951)	(61,373)
Depreciation	2,776	1,643	7	4,426	78	870	5,374
Inventory impairment and non-recurring costs included in cost of sales (2)(5)	5,692	5,889	21	11,602	221	2,501	14,324
Adjusted gross profit (loss) before FV adjustments (1)	24,938	3,450	5	28,393	(129)	4,324	32,588
Adjusted gross margin before FV adjustments (1)	61%	27%	11%	53%	(40%)	22%	44%
Three months ended March 31, 2023(7)
Gross revenue	40,684	18,956	307	59,947	488	10,754	71,189
Excise taxes	(2,681)	(4,465)	-	(7,146)	-	-	(7,146)
Net revenue(1)	38,003	14,491	307	52,801	488	10,754	64,043
Cost of sales	(19,938)	(14,556)	(173)	(34,667)	(646)	(8,032)	(43,345)
Depreciation	2,453	1,773	21	4,247	77	877	5,201
Inventory impairment, non-recurring, out-of-period, and market development costs included in cost of sales (2)(3)(4)(6)	2,555	1,912	25	4,492	96	233	4,821
Adjusted gross profit (loss) before FV adjustments (1)	23,073	3,620	180	26,873	15	3,832	30,720
Adjusted gross margin before FV adjustments (1)	61%	25%	59%	51%	3%	36%	48%
Three months ended June 30, 2022(7)
Gross revenue	39,454	16,994	-	56,448	1,007	-	57,455
Excise taxes	(2,983)	(4,356)	-	(7,339)	-	-	(7,339)
Net revenue(1)	36,471	12,638	-	49,109	1,007	-	50,116
Non-recurring net revenue adjustments (4)	-	1,023		1,023	-	-	1,023
Adjusted net revenue	36,471	13,661		50,132	1,007	-	51,139
Cost of sales	(21,271)	(17,700)	-	(38,971)	(6,323)	-	(45,294)
Depreciation	3,489	2,506	-	5,995	816	-	6,811
Inventory impairment, out-of-period, and non-recurring adjustments included in cost of sales (2)(4)(6)	5,747	5,118	-	10,865	2,230	-	13,095
Adjusted gross profit (loss) before FV adjustments (1)	24,436	3,585	-	28,021	(2,270)	-	25,751
Adjusted gross margin before FV adjustments (1)	67%	26%	- %	56%	(225%)	- %	50%

(1)

These terms are Non-GAAP Measures and are note recognized, defined or standardized measures under IFRS. Refer to the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A.

(2)

Inventory impairment includes inventory write-downs due to lower of cost or net realizable value adjustments, obsolescence provision adjustments, and inventory destruction.

(3)

Markets under development represents the adjustment for business operations focused on developing international markets prior to commercialization.

(4)

Non-recurring items includes one-time excise tax refunds, one-time Reliva returns, inventory count adjustments resulting from facility shutdowns and inter-site transfers, and abnormal spikes to utilities costs on its plant propagation business.

(5)

Non recurring items includes business transformation costs in connection with the re-purposing and ramp-up of the Company’s Sky facility. Inventory provision in Q1 2024 includes a provision of $0.9 million for the potential return and destruction of Reliva CBD inventory resulting from the Company’s decision to wind down its Reliva operations.

(6)

Out-of-period adjustments include adjustments to year-end bonus accruals included in the current quarter but relating to prior quarters and adjustments to input assumptions related to fair value of biological assets.

(7)

Comparative information has been re-presented due to discontinued operations.

 

 

 

Medical Cannabis Adjusted Gross Margin

 

Aurora’s leading medical cannabis businesses in Canada and Europe continued to perform well in Q1 2024 and delivered 77% (Q3 2023 - 75%, Q4 2022 - 95%) of adjusted margin before fair value adjustments. Excluding adjusted gross profit before fair value adjustments from the plant propagation business, the medical cannabis business delivered 88% (Q3 2023 - 86%, Q4 2022 - 95%) of adjusted margin before fair value adjustments.

 

Adjusted gross margin before fair value adjustments on medical cannabis net revenue remained consistent at 61% for the three months ended June 30, 2023 as compared to 61% in Q3 2023, and decreased from 67% in Q4 2022. The decrease is primarily driven by a slightly higher mix towards the international export market which averages a slightly lower adjusted gross margin before fair value adjustments than the Canadian and EU medical markets.

 

Consumer Cannabis Adjusted Gross Margin

 

Adjusted gross margin before fair value adjustments on consumer cannabis net revenue was 27% for the three months ended June 30, 2023, compared to 25% in Q3 2023 and 26% in Q4 2022. The increases are largely due to higher efficiency in production operations relative to comparative periods.

 

Plant Propagation Adjusted Gross Margin

 

Adjusted gross margin before fair value adjustments on plant propagation revenue was 22% for the three months ended June 30, 2023 as compared to 36% in Q3 2023. The decrease in adjusted gross margin before fair value adjustments on plant propagation revenue is due to the seasonality of the Bevo business, driven by sales mix, with a higher volume of lower margin sales in the current quarter.

 

Operating Expenses

	Three months ended
($ thousands)	June 30, 2023	March 31, 2023	June 30, 2022
General and administration	21,874	26,316	30,139
Sales and marketing	12,806	13,408	16,276
Acquisition costs	226	696	3,720
Research and development	1,101	1,656	1,991
Depreciation and amortization	2,861	4,674	11,616
Share-based compensation	2,281	3,620	3,472
Total operating expenses	41,149	50,370	67,214

(1)

Comparative information has been re-presented due to discontinued operations.

 

General and administration (“G&A”)

 

During the three months ended June 30, 2023, G&A expense decreased by $4.4 million and decreased $8.3 million as compared to the prior quarter and to the same period in the prior year, respectively. Included in the three months ended June 30, 2023 G&A expense is $4.1 million in business transformation costs¹ (three months ended March 31, 2023 - $6.3 million, three months ended June 30, 2022 - $6.7 million), $0.6 million of non-recurring costs¹ (three months ended March 31, 2023 - $1.8 million; three months ended June 30, 2022 - $1.1 million), $0.5 million in out-of-period costs¹ (three months ended March 31, 2023 - $0.6 million, three months ended June 30, 2022 - nil), and nil in market development costs¹ (three months ended March 31, 2023 - $1.0 million; three months ended June 30, 2022 - $1.3 million²). Excluding these impacts, Adjusted SG&A³ expense for the three months ended June 30, 2023, March 31, 2023 and June 30, 2022 would have been $16.7 million, $16.6 million, and $21.1 million², respectively. The decrease of $4.4 million as compared to the three months ended June 30, 2022 is primarily due to reductions in corporate headcount and corporate overhead in connection with our previously announced business transformation plans.

 

 

---

¹ These costs are described in the footnotes to the table in the “Adjusted EBITDA” section of this MD&A.

² Recast to be comparable to the current period presentation

³ These terms are Non-GAAP Measures and are not recognized, defined or standardized under IFRS. Refer to the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A.

 

 

 

 

 

Sales and marketing (“S&M”)

 

During the three months ended June 30, 2023, S&M expense decreased by $0.6 million and decreased by $3.5 million as compared to the prior quarter and to the same period in the prior year, respectively. Included during the three months ended June 30, 2023 S&M expense is nil in business transformation costs¹ (three months ended March 31, 2023 - $0.9 million, three months ended June 30, 2022 - $0.1 million), nil of non-recurring costs¹ (three months ended March 31, 2023 - $1.0 million, three months ended June 30, 2022 - nil) and nil in out-of-period adjustments¹ (three months ended March 31, 2023 - $0.2 million, three months ended June 30, 2022 - $2.3 million). Excluding these impacts, Adjusted S&M³ expense for the three months ended June 30, 2023, March 31, 2023 and June 30, 2022 would have been $12.8 million, $11.3 million and $13.8 million, respectively. The increase of $1.5 million as compared to the prior quarter is primarily due to increased commission and shipping costs on higher revenue and sales volumes. The decrease of $1.0 million as compared to the same period of the prior year is largely due to reductions in sales and market development headcount and consultant costs, offset partially from increased commission and shipping costs on higher revenue and sales volumes.

 

The table below outlines Adjusted SG&A for the periods ended:

 

	Three months ended
($ thousands)	June 30, 2023	March 31, 2023	June 30, 2022
Sales and marketing	12,806	13,408	16,276
General and administration	21,874	26,316	30,139
Business transformation costs	(4,063)	(7,209)	(6,812)
Out-of-period adjustments	(544)	(818)	(2,349)
Non-recurring costs	(593)	(2,837)	(1,127)
Market development costs	-	(958)	(1,288)
Adjusted SG&A (1)	29,480	27,902	34,839

(1)

Adjusted SG&A is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A.

 

Research and development (“R&D”)

 

During the three months ended June 30, 2023, R&D expenses decreased by $0.6 million and decreased by $0.9 million as compared to the prior quarter and to the same period in the prior year, respectively. The decrease from the prior quarter relates primarily to a more targeted and gated approach to product innovation. The decrease compared to the same period in prior year relates primarily to reductions in research and development headcount.

 

The table below outlines Adjusted R&D for the periods ended:

 

	Three months ended
($ thousands)	June 30, 2023	March 31, 2023	June 30, 2022
Research and development	1,101	1,656	1,991
Out-of-period adjustments	-	(63)	-
Share-based compensation	-	(44)	-
Adjusted R&D (1)	1,101	1,549	1,991

(1)

Adjusted SG&A is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A.

 

Depreciation and amortization

 

During the three months ended June 30, 2023 depreciation and amortization expense decreased by $1.8 million and decreased by $8.8 million as compared to the prior quarter and the same period in the prior year, respectively. The decrease from the prior quarter is primarily due to asset disposals. The decrease from the same period in the prior year is due to facility disposals and asset impairment charges recognized at the end of fiscal 2022.

 

Share-based compensation

 

During the three months ended June 30, 2023, share-based compensation expense decreased by $1.3 million and $1.2 million compared to the prior quarter and the same period in the prior year, respectively. The decrease is primarily due to higher than expected forfeitures and expirations.

 

Other Income (Expense)

 

During the three months ended June 30, 2023, other income (expense) was $(6.0) million and consisted mainly of: (i) $(5.3) million in finance costs; (ii) $(3.6) million in foreign exchange gains, partially offset by $3.4 million in interest income.

 

 

Net Loss

 

Net loss from continuing operations for the three months ended June 30, 2023 was $22.2 million compared to $76.9 million in the prior quarter and $617.0 million for the same period in the prior year. The decrease in net loss of $54.7 million from the prior quarter was primarily attributable to $42.2 million in other expenses caused by impairments of property, plant and equipment, intangible assets and goodwill, partially offset by an increase in gross profit of $6.5 million and a decrease of $9.2 million in operating expenses. The decrease in net loss of $594.8 million from the same period in the prior year was primarily due to a decrease in other expenses of $552.3 million, primarily consisting of (i) a decrease of $457.5 million in impairment of intangible assets and goodwill and (ii) a decrease of $78.7 million in impairment of property, plant and equipment, in addition to an increase in gross profit of $17.9 million and lower operating expenses of $26.1 million in the current period.

 

Adjusted EBITDA

 

The following is the Company’s adjusted EBITDA:

($ thousands)	Three months ended
	June 30, 2023	March 31, 2023	June 30, 2022
Net loss from continuing operations	(22,204)	(76,884)	(617,021)
Income tax expense (recovery)	96	(3,109)	(1,363)
Other income (expense)	5,994	48,154	558,300
Share-based compensation	2,281	3,620	3,472
Depreciation and amortization	8,288	9,875	18,459
Acquisition costs	226	696	3,720
Inventory and biological assets fair value and impairment adjustments(6)	(2,436)	6,719	9,007
Business transformation related charges (1)	6,564	7,253	6,812
Out-of-period adjustments (2)	544	1,333	1,833
Non-recurring items (3)	2,802	2,425	6,736
Markets under development (4)	-	1,172	1,288
Adjusted EBITDA (5)	2,155	1,254	(8,757)

(1)

Business transformation related charges includes costs related to closed facilities, certain IT project costs, costs associated with the repurposing of Sky, severance and retention costs in connection with the business transformation plan, costs associated with the retention of certain medical aggregators, and payroll costs exited prior to the end of Q2 2023 associated with the medical cannabis business.

(2)

Out-of-period adjustments reflect adjustments to net loss for the financial impact of transactions recorded in the current period that relate to prior periods.

(3)

Non-recurring items includes one-time excise tax refunds, non-core adjusted wholesale bulk margins, inventory count adjustments resulting from facility shutdowns and inter-site transfers, litigation and non-recurring project costs, an abnormal mildew issue on certain cultivation lots, additional expenses associated with the change in fiscal year end to March 31, 2023, one-time break fees with certain vendors, and temporary abnormal utilities costs within the plant propagation business.

(4)

Markets under development represents the adjustment for business operations focused on developing international markets prior to commercialization.

(5)

Adjusted EBITDA is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of the MD&A. Prior period comparatives were recast to include the adjustments for markets under development, business transformation costs, and non-recurring charges related to non-core bulk cannabis wholesales to be comparable to the current period presentation.

(6)

Year ended June 30, 2022 comparative was recast to include inventory impairment adjustments to be comparable to the current period presentation.

 

 

Adjusted EBITDA was $2.2 million for the three months ended June 30, 2023, as compared to Adjusted EBITDA of $1.3 million for the three months ended March 31, 2023 and Adjusted EBITDA loss of $8.8 million for the three months ended June 30, 2022, representing Adjusted EBITDA increases of $0.9 million and increases of $10.9 million, respectively. The sequential increase in Adjusted EBITDA is largely due to higher adjusted gross profits before fair value adjustments of $1.9 million. The increase in Adjusted EBITDA as compared to June 30, 2022 is primarily attributable to higher adjusted gross profits before fair value adjustments of $6.8 million, and reduction in adjusted SG&A and R&D expenses of $6.2 million.

 

 

 

 

Liquidity and Capital Resources

($ thousands)	June 30, 2023	March 31, 2023
Cash and cash equivalents	157,855	234,942
Restricted cash	65,655	65,900
Working capital (1)	227,312	237,622
Total assets	832,188	926,322
Total non-current liabilities	152,257	166,880
Capitalization
Convertible notes	65,107	132,571
Loans and borrowings	44,550	45,734
Lease liabilities	46,727	49,217
Total debt	156,384	227,522
Total equity	507,932	517,137
Total capitalization	664,316	744,659

¹Working Capital is a Non-GAAP Measure and is not a recognized, defined, or a standardized measure under IFRS. Refer to the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A.

 

During the three months ended June 30, 2023, the Company primarily financed its operations, capital expenditures and growth initiatives through the generation of net revenue, working capital, the ATM, and cash on hand. For more information on key cash flows related to operations, investing and financing activities during the quarter, refer to the “Cash Flow Highlights” discussion below.

 

The Company’s objective when managing its liquidity and capital resources is to maintain sufficient liquidity to support financial obligations when they come due, while executing operating and strategic plans. The Company manages liquidity risk through the management of its capital structure and resources to ensure that it has sufficient liquidity to settle obligations and liabilities when they are due. Our ability to fund our operating requirements depends on future operating performance and cash flows, which are subject to economic, financial, competitive, business and regulatory conditions, and other factors, some of which are beyond our control. Our primary short-term liquidity needs are to fund our net operating losses and capital expenditures to maintain existing facilities, convertible debenture repayment and lease payments. Our medium-term liquidity needs primarily relate to lease payments and our long-term liquidity needs primarily relate to potential strategic plans.

 

As of June 30, 2023, the Company has access to the following capital resources available to fund operations and obligations:

 

•

$157.9 million cash and cash equivalents; and

•

access to the 2023 Shelf Prospectus. The Company currently has access to securities registered for sale under the 2023 Shelf Prospectus currently covering US$650.0 million of issuable securities. Of the U.S.$650 million of securities registered under the 2023 Shelf Prospectus and corresponding registration statement on form F-10 filed with the U.S. Securities and Exchange Commission in the U.S., approximately U.S.$409 million is allocated to the potential exercise of currently outstanding warrants issued in financing transactions from 2020 to 2022. As a result, approximately U.S.$241 million is available for potential new issuances of Common Shares, warrants, options, subscription receipts, debt securities or any combination thereof during the 25-month period that the 2023 Shelf Prospectus remains effective. Volatility in the cannabis industry, stock market and the Company’s share price may impact the amount and our ability to raise financing under the 2023 Shelf Prospectus

 

Based on all of the aforementioned factors, the Company believes that its reduction of operating costs, current liquidity position, and access to the 2023 Shelf Prospectus are adequate to fund operating activities and cash commitments for investing, financing and strategic activities for the foreseeable future. In addition, the Company could access restricted cash of $20.5 million relating to its self insurance policy, if necessary.

 

As of July 31, 2023, the Company had approximately $214.2 million of cash on hand, including $65.6 million of restricted cash and had $63.4 million outstanding in convertible debentures. The Company believes its cash on hand is sufficient to fund operations until the Company is cash flow positive. Additionally, the Company has access to approximately U.S.$241 million under the 2023 Shelf Prospectus, as described above.

 

Credit Facility

On April 11, 2023, the Credit Agreement was amended to reduce the amounts available to be drawn from the Term Loan by $9.7 million to $38.1 million and increase the amounts available to be drawn from the Revolver by $4.0 million to $12.0 million. Additionally, there were changes to the financial covenants. There were nominal costs incurred for the amendments.

The term loans consist of the following access to funds under the credit facility:

i.

a $38.1 million term loan (“Term Loan”), previously $47.8 million; and

ii.

a $12.0 million revolving line of credit (“Revolver”), previously $8.0 million.

On April 11, 2023, the Credit Agreement was amended to reduce the amounts available to be drawn from the Term Loan by $9.7 million to $38.1 million and increase the amounts available to be drawn of the Revolver by $4.0 million to $12.0 million. Additionally, there were changes to the financial covenants. There were nominal costs incurred for the amendments that have been recorded as a finance expense in the consolidated statements of loss and comprehensive loss.

 

 

Term loan

 

As at June 30, 2023, advances under the Term Loan were made in two tranches, with interest payments based on prime rate plus a margin. Interest is due monthly and the principal balance is repayable in equal quarterly installments of 1/60th of the amount borrowed. As at June 30, 2023, the borrowing rate was 4.905%. Each tranche is scheduled to mature on January 21, 2025. Any remaining principal balance will be due at maturity. During the three months ended June 30, 2023, total interest expense of $0.6 million was recognized as finance and other costs in the condensed consolidated interim statements of loss and comprehensive loss. As at June 30, 2023, the total term loan payable is $37.1 million.

 

Revolver

 

The Revolver provides available aggregate borrowings of up to $12.0 million. Interest payments are based on prime plus a margin that ranges between 0.25% and 1.75%. As at June 30, 2023, $7.3 million was drawn from the revolver loan.

 

Total loans and borrowings principal repayments as at June 30, 2023 are as follows:

 

	$
Next 12 months	9,439
Over 1 year to 2 years	2,639
Over 2 years to 5 years	6,766
Over 5 years	25,706
Total long-term debt repayments	44,550

 

Cash Flow Highlights

 

The table below summarizes the Company’s cash flows for the periods ended June 30, 2023 and the comparative periods:

($ thousands)	Three months ended
	June 30, 2023	June 30, 2022
Cash used in operating activities	(11,237)	(26,642)
Cash provided by (used in) investing activities	(2,158)	(39,736)
Cash provided by (used in) financing activities	(61,943)	62,039
Effect of foreign exchange	(1,749)	12,252
Decrease in cash and cash equivalents	(77,087)	7,913

 

Cash used in operating activities for the three months ended June 30, 2023 decreased by $15.4 million, to $11.2 million as compared to the three months ended June 30, 2022. Excluding changes in non-cash working capital, cash used in operating activities during the three months ended June 30, 2023 was $14.8 million compared to $37.5 million for the three months ended June 30, 2022. The improvement of $22.6 million is largely due to the restructuring of the Company which was announced and initiated during fiscal year 2022.

 

Cash used in investing activities for the three months ended June 30, 2023 decreased by $37.6 million to $2.2 million as compared to the three months ended June 30, 2022. The decrease was primarily due to a reduction in capital expenditures compared to prior year comparative period, offset by monetizing property, plant and equipment no longer required as a result of the restructuring of the business and streamlining operations.

 

Cash used in financing activities for the three months ended June 30, 2023 decreased by $124.0 million to $61.9 million as compared to the three months ended June 30, 2022. The decrease was primarily due to i) lower proceeds received from the issuance of shares of $208.2 million and ii) reduced repayments of convertible debentures. During the three months ended June 30, 2023, the Company repaid $61.9 million of its convertible debentures whereas during the three months ended June 30, 2022, it repaid $145.7 million.

 

Capital Expenditures

 

During the three months ended June 30, 2023, capital expenditures including intangible assets was $4.3 million, partially offset by $2.4 million in proceeds from disposals.

 

 

Contractual Obligations

 

As at June 30, 2023, the Company had the following undiscounted contractual obligations:

($ thousands)	Total	≤ 1 year	Over 1 year to 3 years	Over 3 years to 5 years	> 5 years
Accounts payable and accrued liabilities	62,482	62,482	-	-	-
Convertible notes and interest (1)	70,006	70,006	-	-	-
Lease liabilities (2)	97,034	8,244	21,223	14,350	53,217
Loans and borrowings, principal repayment	44,550	9,439	2,639	6,766	25,706
Contingent consideration payable (3)	12,964	2,610	10,354	-	-
Capital commitments (4)	2,202	2,202	-	-	-
Total contractual obligations	289,238	154,983	34,216	21,116	78,923

(1)

Assumes the remaining principal balance outstanding at June 30, 2023 remains unconverted and includes the estimated interest payable until the maturity date.

(2)

Includes interest payable until maturity date.

(3)

Payable in cash, shares, or a combination of both at Aurora’s sole discretion.

(4)

Relates to remaining commitments that the Company has made to vendors for equipment purchases and capital projects pertaining to existing construction.

 

Contingencies

 

From time to time, the Company and/or its subsidiaries may become defendants in legal actions and the Company intends to take appropriate action with respect to any such legal actions, including by defending itself against such legal claims as necessary. Other than the claims described below, as of the date of this report, Aurora is not aware of any other material or significant claims against the Company.

 

On November 21, 2019, a purported class action proceeding was commenced in the United States District Court for the District of New Jersey against the Company and certain of its current and former directors and officers on behalf of persons or entities who purchased, or otherwise acquired, publicly traded Aurora securities between October 23, 2018 and February 6, 2020. An amended complaint was filed on September 21, 2020 which alleges, inter alia, that the Company and certain of its current and former officers and directors violated the federal securities laws by making false or misleading statements, materially overstated the demand and potential market for the Company’s consumer cannabis products; that the Company’s ability to sell products had been materially impaired by extraordinary market oversupply, that the Company’s spending growth and capital commitments were slated to exceed our revenue growth; that the Company had violated German law mandating that companies receive special permission to distribute medical products exposed to regulated irradiation techniques, and that the foregoing, among others, had negatively impacted the Company’s business, operations, and prospects and impaired the Company’s ability to achieve profitability. A motion to dismiss was filed on November 20, 2020 and granted by the court on July 7, 2021, however, the plaintiffs were given an opportunity to file a second amended complaint no later than September 7, 2021. Pursuant to the July 7, 2021 order, the plaintiffs filed a second amended complaint on September 7, 2021 which included new allegations pertaining to certain alleged financial misrepresentation and improper revenue recognition by the Company. The Company subsequently filed a motion to dismiss on December 6, 2021 and a reply to plaintiffs’ opposition on March 25, 2022. Again, on a judgement dated September 23, 2022 the Court granted the second motion to dismiss the case in favour the Company. The motion was granted without prejudice. The plaintiff’s counsels re-filed a third statement of claim on November 7, 2022 and the re-stated claim was received by Aurora formally on November 8, 2022. The Company filed a third further motion to dismiss on January 6, 2023, to which the plaintiffs have filed an opposition brief and the Company subsequently filed a reply. While this matter is ongoing, the Company disputes the allegations and intends to continue to vigorously defend against the claims. Estimating an amount or range of possible losses resulting from litigation proceedings is inherently difficult, particularly where the matters involve indeterminate claims for monetary damages and are in the stages of the proceedings where key factual and legal issues have not been resolved. For these reasons, the Company is currently unable to predict the ultimate timing or outcome of or reasonably estimate the possible losses or a range of possible losses resulting from the matters described above.

 

The Company and its subsidiary, ACE, have been named in a purported class action proceeding which commenced on June 16, 2020 in the Province of Alberta in relation to the alleged mislabeling of cannabis products with inaccurate THC/CBD content. The class action involves a number of other parties including Aleafia Health Inc., Hexo Corp, Tilray Canada Ltd., among others, and alleges that upon laboratory testing, certain cannabis products were found to have lower THC potency than the labeled amount, suggesting, among other things, that plastic containers may be leeching cannabinoids. While this matter is ongoing, the Company disputes the allegations and intends to vigorously defend against the claims. Estimating an amount or range of possible losses resulting from litigation proceedings is inherently difficult, particularly where the matters involve indeterminate claims for monetary damages and are in the stages of the proceedings where key factual and legal issues have not been resolved. For these reasons, the Company is currently unable to predict the ultimate timing or outcome of or reasonably estimate the possible losses or a range of possible losses resulting from the matter described above.

 

A claim was commenced by a party to a former term sheet on June 15, 2020 with the King's Bench of Alberta against Aurora and a former officer alleging a claim of breach of obligations under said term sheet, with the plaintiff seeking $18.0 million in damages. While this matter is ongoing, the Company believes the action to be without merit and intends to defend the claim.

 

On August 10, 2020, a purported class action lawsuit was filed with the King's Bench of Alberta against Aurora and certain executive officers in the Province of Alberta on behalf of persons or entities who purchased, or otherwise acquired, publicly traded Aurora securities and suffered losses as a result of Aurora releasing statements containing misrepresentations during the period of September 11, 2019 and December 21, 2019. Chambers appointment has been scheduled for January 2024. The Company disputes the allegations and intends to vigorously defend against the claims. Estimating an amount or range of possible losses resulting from litigation proceedings is inherently difficult, particularly where the matters involve indeterminate claims for monetary damages and are in the stages of the proceedings where key factual and legal issues have not been resolved. For these reasons, the Company is currently unable to predict the ultimate timing or outcome of or reasonably estimate the possible losses or a range of possible losses resulting from the matter described above.

 

 

On January 4, 2021, a civil claim was filed with the King’s Bench of Alberta against Aurora and Hempco by a former landlord regarding unpaid rent in the amount of $8.9 million, representing approximately $0.4 million for rent in arrears and costs, plus $8.5 million for loss of rent and remainder of the term. The Company filed a statement of defense on March 24, 2021. Plaintiffs were to bring a summary judgement application which is being opposed by Aurora and which application will likely not be heard until 2024. Questioning on Affidavits is scheduled to begin in the Fall of 2023. While this matter is ongoing, the Company intends to continue to defend against the claims

 

The Company, its subsidiary ACE, and MedReleaf Corp. (which amalgamated with ACE in July 2020) have been named in a purported class action proceeding commenced on November 15, 2022 in the Ontario Superior Court of Justice. The purported class action claims that the Company failed to warn of certain risks purported to be associated with the consumption of cannabis. The Statement of Claim was served upon the Company on November 22, 2022 and a Statement of Defence was filed and served. The next major step in the process is scheduling a timetable for the remaining deliverables of the process, including delivery of the plaintiff’s certification motion record. The plaintiff must either deliver their certification materials or come to an agreement with the Aurora Defendants on a timetable for doing so within one year of commencing the proposed class action. The Court has issued an order allowing the representative plaintiff to remain anonymized in all court documents, including identifying her by “V.T”. The Company disputes the allegations and intends to defend against the claims.

 

On May 5, 2022, Aurora Cannabis Inc. acquired all issued and outstanding shares of Terrafarma Inc. Terrafarma Inc. is now a wholly owned subsidiary of Aurora Cannabis Inc. Prior to Aurora’s acquisition of Terrafarma, a former employee of Terrafarma commenced a claim for wrongful dismissal seeking damages in the amount $1,046,400 plus additional damages relating to certain options and unpaid bonus. The Company disputes the allegations and intends to defend against the claims.

 

A claim was commenced by a former employee of Aurora against Aurora Cannabis Enterprises Inc. and another former employee of Aurora (the “Defendant Employee”). The plaintiffs claim that the Defendant Employee entered a lease for a property owned by the plaintiffs in January 2017 and states that Aurora was a guarantor for the Defendant Employee. The claim states that the Defendant Employee left the property and caused damage. The plaintiffs further claim outstanding rent and legal fees. There is no record of any documentation of Aurora being a party to any such relationship. The Defendant Employee has been noted in default by the plaintiff and Aurora has filed and served a Third-Party Notice against the Defendant Employee. The Company disputes the allegations and intends to defend against the claims.

 

The Company is subject to litigation and similar claims in the ordinary course of our business, including claims related to employment, human resources, product liability and commercial disputes. The Company has received notice of, or are aware of, certain possible claims against us where the magnitude of such claims is negligible, or it is not currently possible for us to predict the outcome of such claims, possible claims or lawsuits due to various factors including: the preliminary nature of some claims; an incomplete factual record; and the unpredictable nature of opposing parties and their demands. Management is of the opinion, based upon legal assessments and information presently available, that it is unlikely that any of these claims would result in liability to the Company, to the extent not provided for through insurance or otherwise, would have a material effect on the consolidated financial statements, other than the claims described above.

 

In respect of the aforementioned claims, as at June 30, 2023 the Company has recognized total provisions of $1.0 million (June 30, 2022 - nil) in provisions on the consolidated statements of financial position and a settlement accrual for $1.0 million (June 30, 2022 - nil) in accounts payable and accrued liabilities on the consolidated statements of financial position.

 

Off-balance sheet arrangements

 

As at the date of this MD&A, the Company has $0.9 million letters of credit outstanding with the Bank of Montreal. There are no other material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the financial performance or financial condition of the Company.

 

Related Party Transactions

 

The Company’s key management personnel consists of the Company’s executive management team and management directors who, collectively, have the authority and responsibility for planning, directing and controlling the activities of the Company and. Compensation expense for key management personnel was as follows:

 

($ thousands)	Three months ended
	June 30, 2023	June 30, 2022
Short-term employment benefits (1)	1,773	1,858
Long-term employment benefits	11	13
Termination benefits	-	308
Directors’ fees (2)	103	85
Share-based compensation (3)	2,300	2,600
Total management compensation (4)	4,187	4,864

(1)

Short-term employment benefits include salaries, wages, and bonuses. Short-term employment benefits are measured at the exchange value, being the amounts agreed to by each party.

(2)

Includes meeting fees and committee chair fees.

(3)

Share-based compensation represent the contingent consideration, and the fair value of options, restricted share units, deferred share units and performance share units granted and vested to key management personnel and directors of the Company under the Company’s share-based compensation plans (refer to Note 12 of the Consolidated Financial Statements).

(4)

As of June 30, 2023, $2.5 million is payable or accrued for key management compensation (March 31, 2023 - $1.6 million).

 

 

The following is a summary of the significant transactions with related parties:

($ thousands)	Three months ended
	June 30, 2023	June 30, 2022
Production costs (1)	-	1,602

(1)

Production costs incurred with (i) Gelcan Corporation, a company that manufactures softgels; and (ii) Sterigenics Radiation Technologies, formerly Iotron Industries Canada Inc.. Pursuant to a manufacturing agreement, the Company was contractually committed to purchase a minimum number of softgels each calendar year. During the three months ended December 31, 2022 the Company terminated the manufacturing agreement.

 

The following amounts were receivable from (payable to) related parties:

($ thousands)	June 30, 2023	March 31, 2023
Production costs with investments in associates (1)	-	439

(1)

Production costs incurred with (i) Gelcan Corporation, a company that manufactures softgels; and (ii) Sterigenics Radiation Technologies, formerly Iotron Industries Canada Inc.). Pursuant to a manufacturing agreement, the Company was contractually committed to purchase a minimum number of softgels each calendar year. During the three months ended December 31, 2022 the Company terminated the manufacturing agreement.

 

These transactions are in the normal course of operations and are measured at the exchange value, being the amounts agreed to by the parties.

 

Critical Accounting Estimates

 

The preparation of the Financial Statements under IFRS requires management to make judgments, estimates, and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

 

There have been no changes in Aurora's critical accounting estimates during the three months ended June 30, 2023. For additional information on the Company’s accounting policies and key estimates, refer to the note disclosures in the annual consolidated financial statements and MD&A as at and for the year ended March 31, 2023.

 

Adoption of New Accounting Pronouncements

 

Amendments to IAS 1: Classification of Liabilities as Current or Non-current

 

The amendment clarifies the requirements relating to determining if a liability should be presented as current or non-current in the statement of financial position. Under the new requirement, the assessment of whether a liability is presented as current or non-current is based on the contractual arrangements in place as at the reporting date and does not impact the amount or timing of recognition. The amendment applies retrospectively for annual reporting periods beginning on or after January 1, 2023. There were no changes to the Company’s current period or comparative period upon adoption.

 

Amendments to IAS 12: Income Taxes

 

The amendment clarifies how companies account for deferred tax on transactions such as leases and decommissioning obligations. The amendments are effective for annual periods beginning on or after January 1, 2023. There was no material impact as a result of adopting these amendments.

 

Amendments to IAS 12: Deferred Tax related to Assets and Liabilities arising from a Single Transaction

 

The amendment narrowed the scope of certain recognition exemptions so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences. An entity applies the amendments to transactions that occur on or after the beginning of the earliest comparative period presented. It also, at the beginning of the earliest comparative period presented, recognizes deferred tax for all temporary differences related to leases and decommissioning obligations and recognizes the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings (or other component of equity, as appropriate) at that date. The amendment is effective for annual periods beginning on or after January 1, 2023 with early application permitted. The Company early adopted these amendments with the adoption of IFRS 16, Leases and therefore there are no changes to the current and comparative periods presented in the consolidated financial statements. The Company has not had any decommissioned obligations to account for hereunder.

 

IFRS 17 - Insurance Contracts

 

IFRS 17 establishes the principles for the recognition, measurement, presentation and disclosure of insurance contracts within the scope of the standard. The objective of IFRS 17 is to ensure that an entity provides relevant information that faithfully represents those contracts. The standard is effective for annual periods beginning on or after January 1, 2023. The Company does not currently have any contracts to be accounted for under this standard. The Company, however has a wholly owned captive insurance company where its the sole policyholder that is required to adopt this standard when reporting on a stand alone basis. The impact of the captive insurance company adopting IFRS 17 was immaterial to the Company’s consolidated financial statements.

 

 

Amendments to IAS 16: Leases

 

The amendment clarifies how a seller-lessee subsequently measures sale and leaseback transactions that satisfy the requirements in

IFRS 15: Revenue to be accounted for as a sale. The amendment is effective for annual periods beginning on or after January 1, 2024. The Company does not have any sale-leaseback transaction

 

New Accounting Pronouncements Not Yet Adopted

 

The following IFRS standards have been recently issued by the IASB. Pronouncements that are irrelevant or not expected to have a significant impact have been excluded.

 

Amendments to IAS 1: Covenants

 

The amendment that clarify how an entity classifies debt and other financial liabilities as current or non-current in particular circumstances. The amendments are effective for annual periods beginning on or after January 1, 2024. Management is currently evaluating the potential impact of this standard on the Company’s consolidated financial statements.

 

Financial Instruments

Financial instruments are measured either at fair value or at amortized cost. The table below lists the valuation methods used to determine the fair value of each financial instrument.

	Fair Value Method
Financial Instruments Measured at Fair Value
Marketable securities	Closing market price of Common Shares as of the measurement date (Level 1)
Derivatives	Closing market price (Level 1) or Black-Scholes, Binomial, Monte-Carlo & FINCAD valuation model (Level 2 or 3)
Contingent consideration payable	Discounted cash flow model (Level 3)
Derivative liability	Closing market price of warrants (Level 1) or Kynex valuation model (Level 2)
Financial Instruments Measured at Amortized Cost
Cash and cash equivalents, restricted cash, accounts receivable, loans receivable	Carrying amount (approximates fair value due to short-term nature)
Accounts payable and accrued liabilities, other current and long-term liabilities, loans and borrowings	Carrying amount (approximates fair value due to short-term nature)
Lease receivable, convertible debentures, loans and borrowings, and lease liabilities.	Carrying value discounted at the effective interest rate which approximates fair value

Summary of Financial Instruments

The carrying values of the financial instruments at June 30, 2023 are summarized in the following table:

($ thousands)	Amortized cost	FVTPL	Designated FVTOCI	Total
	$	$	$	$
Financial Assets
Cash and cash equivalents	157,855	-	-	157,855
Restricted cash	65,655	-	-	65,655
Accounts receivable, excluding sales taxes and lease receivable	30,095	-	-	30,095
Derivatives	-	7,422	-	7,422
Lease receivable	10,481	-	-	10,481
Financial Liabilities
Accounts payable and accrued liabilities	62,482	-	-	62,482
Convertible debentures	65,107	-	-	65,107
Contingent consideration payable	-	12,964	-	12,964
Other current liabilities	12,635	-	-	12,635
Lease liabilities	46,727	-	-	46,727
Derivative liability	-	5,945	-	5,945
Loans and borrowings	44,550	-	-	44,550
Other long-term liabilities	50,230	-	-	50,230

 

 

 

Fair Value Hierarchy

 

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The three levels of hierarchy are:

Level 1	Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2	Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and
Level 3	Inputs for the asset or liability that are not based on observable market data.

 

The following is a summary of financial instruments measured at fair value segregated based on the various levels of inputs as at June 30, 2023:

($ thousands)	Level 1	Level 2	Level 3	Total
As at June 30, 2023
Derivative assets (1)	-	7,422	-	7,422
Contingent consideration payable	-	-	12,964	12,964
Derivative liability (2)	5,945	-	-	5,945
As at March 31, 2023
Marketable securities	-	-	-	-
Derivative assets	-	7,114	135	7,249
Contingent consideration payable	-	-	12,487	12,487
Derivative liability	9,634	-	-	9,634

(1)

For a reconciliation of realized and unrealized gains and losses applicable to financial assets measured at fair value for the nine months ended June 30, 2023, refer to Note the Financial Statements.

(2)

For a reconciliation of unrealized gains and losses applicable to financial liabilities measured at fair value for the nine months ended June 30, 2023, refer to Note 8 and Note 11(c) in the Financial Statements.

 

There have been no transfers between fair value levels during the period.

 

Financial Instruments Risk

 

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board mitigates these risks by assessing, monitoring and approving the Company’s risk management processes.

 

Credit risk

 

Credit risk is the risk of a potential loss to the Company if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company is moderately exposed to credit risk from its cash and cash equivalents, accounts receivable and loans receivable. The risk exposure is limited to their carrying amounts reflected on the statement of financial position. The risk for cash and cash equivalents is mitigated by holding these instruments with highly rated Canadian financial institutions. Certain restricted funds in the amount of are retained by an insurer under the Segregated Accounts Companies Act governed by the Bermuda Monetary Authority. As the Company does not invest in asset-backed deposits or investments, it does not expect any credit losses. The Company periodically assesses the quality of its investments and is satisfied with the credit rating of the financial institutions and the investment grade of its Guaranteed Investment Certificates (“GICs”). The Company mitigates the credit risk associated with the loans receivable by managing and monitoring the underlying business relationship.

 

The Company provides credit to certain customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Credit risk is generally limited for receivables from government bodies, which generally have low default risk. Credit risk for non-government wholesale customers is assessed on a case-by-case basis and a provision is recorded where required. As of June 30, 2023, $20.4 million of accounts receivable, net of allowances, are from non-government wholesale customers (March 31, 2023 - $20.9 million). As of June 30, 2023, the Company recognized a $1.6 million provision for expected credit losses (March 31, 2023 - $3.4 million).

 

 

 

For the periods indicated, the Company’s aging of trade receivables were as follows:

($ thousands)	June 30, 2023	March 31, 2023
0 - 60 days	23,571	28,355
61+ days	6,265	6,661
	29,836	35,016

 

Liquidity risk

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with its financial liabilities when they are due. The Company’s objective is to manage liquidity risk through the management of its capital structure and resources to ensure that it has sufficient liquidity to settle obligations and liabilities when they are due, while executing on its operating and strategic plans. Refer to “Liquidity and Capital Resources” section of this MD&A for detailed discussion.

 

Summary of Outstanding Share Data

 

The Company had the following securities issued and outstanding as at August 9, 2023 :

Securities (1)	Units Outstanding
Issued and outstanding Common Shares	376,836,255
Stock options	12,383,538
Warrants	89,124,788
Restricted share units	9,263,314
Deferred share units	1,305,189
Performance share units	7,309,626
Convertible debentures	551,670

(1)

Refer to Note 8 “Convertible Debentures”, Note 11 “Share Capital” and Note 12 “Share-Based Compensation” in the Financial Statements for a detailed description of these securities.

 

 

 

Historical Quarterly Results

 

($ thousands, except earnings per share and Operational Results)	June 30, 2023	March 31, 2023(6)	December 31, 2022(6)	September 30, 2022(6)
Financial Results
Net revenue (2)	$75,110	$64,043	$61,679	$49,263
Adjusted gross margin before FV adjustments on total net revenue (3)	44%	48%	45%	50%
Loss from continuing operations attributable to common shareholders (4)	($20,771)	($71,661)	($61,040)	($51,463)
Loss from discontinued operations attributable to common shareholders	($6,127)	($10,341)	($4,352)	($141)
Loss attributable to common shareholders	($26,898)	($82,002)	($65,392)	($51,604)
Basic and diluted loss per share from continuing operations	($0.06)	($0.21)	($0.20)	($0.17)
Basic and diluted loss per share	($0.08)	($0.24)	($0.20)	($0.17)
Balance Sheet
Working capital	$227,312	$237,622	$409,729	$514,193
Cannabis inventory and biological assets (4)	$100,846	$93,081	$93,675	$121,776
Total assets	$832,188	$926,322	$1,023,835	$1,169,927
Operational Results - Cannabis
Average net selling price of dried cannabis (3)	$4.81	$4.76	$4.79	$5.32
Kilograms sold	15,682	16,578	15,269	12,165
	June 30, 2022(6)	March 31, 2022(6)	December 31, 2021(6)	September 30, 2021(6)
Financial Results
Net revenue (2)	$50,116	$50,434	$60,586	$60,108
Adjusted gross margin before FV adjustments on total net revenue (3)	47%	54%	53%	54%
Loss from continuing operations attributable to common shareholders (4)	($617,032)	($1,011,565)	($74,213)	($4,771)
Loss from discontinued operations attributable to common shareholders	($1,755)	($612)	($563)	($7,113)
Loss attributable to common shareholders	($618,787)	($1,012,177)	($74,776)	($11,884)
Basic and diluted loss per share from continuing operations	($2.48)	($4.72)	($0.38)	($0.06)
Basic and diluted loss per share	($2.48)	($4.72)	($0.38)	($0.06)
Balance Sheet
Working capital	$614,264	$577,566	$481,574	$532,612
Cannabis inventory and biological assets (5)	$127,836	$118,729	$139,625	$139,103
Total assets	$1,084,356	$1,570,252	$2,485,384	$2,560,316
Operational Results - Cannabis
Average net selling price of dried cannabis (2)(3)	$5.09	$5.41	$4.52	$4.67
Kilograms sold	13,130	9,722	13,043	12,484

(1)

Certain previously reported amounts have been restated to exclude the results related to discontinued operations and recast for the biological assets and inventory non-material prior period error. For further details on the recast for biological asset and inventory, refer to the “Change in Accounting Policies and Estimates” section of the Company’s audited consolidated financial statements as at and for the year ended June 30, 2022 and the accompanying notes thereto.

(2)

Net revenue represents our total gross revenue net of excise taxes levied by the CRA on the sale of medical and consumer use cannabis products. Given that our gross revenue figures exclude excise taxes that were levied and billed back to customers, as reflected in accordance with IFRS 15, we believe that the presentation of net revenue more accurately reflects the level of revenue earned during the relevant period.

(3)

Adjusted gross margin before FV adjustments” is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of this MD&A.

(4)

Loss from continuing operations attributable to common shareholders includes asset impairment and restructuring charges. Refer to “Adjusted EBITDA” section.

(5)

Represents total biological assets and inventory, exclusive of merchandise, accessories, supplies, consumables and plant propagation biological assets.

(6)

Comparative information has been re-presented due to discontinued operations.

 

Risk Factors

 

In addition to the other information included in this report, readers should consider carefully the following factors, which describe the risks, uncertainties and other factors that may materially and adversely affect our business, products, financial condition and operating results. There are many factors that affect our business and our results of operations, some of which are beyond our control. The following is a description of important factors that may cause our actual results of operations in future periods to differ materially from those currently expected or discussed in the forward-looking statements (“FLS”) set forth in this report relating to our financial results, operations and business prospects. Except as required by law, we undertake no obligation to update any such FLS to reflect events or circumstances after the date of this MD&A.

 

 

 

 

These risks include, but are not limited to the following:

 

•

We have a limited operating history and there is no assurance that we will be able to achieve or maintain profitability.

•

Our business is reliant on the good standing of our licenses.

•

Our Canadian licenses are reliant on our established sites.

•

We operate in a highly regulated business and any failure or significant delay in obtaining applicable regulatory approvals could adversely affect our ability to conduct our business.

•

Change in the laws, regulations, and guidelines that impact our business may cause adverse effects on our operations.

•

Failure to comply with anti-money laundering laws and regulation could subject us to penalties and other adverse consequences.

•

We compete for market share with a number of competitors and expect even more competitors to enter our market, and many of our current and future competitors may have longer operating histories, more financial resources, and lower costs than us.

•

Selling prices and the cost of cannabis production may vary based on a number of factors outside of our control.

•

We may not be able to realize our growth targets or successfully manage our growth.

•

The continuance of our contractual relations with provincial and territorial governments cannot be guaranteed.

•

Our continued growth may require additional financing, which may not be available on acceptable terms or at all.

•

Any default under our existing debt that is not waived by the applicable lenders could materially adversely impact our results of operations and financial results and may have a material adverse effect on the trading price of our Common Shares.

•

We may be subject to credit risk.

•

We may not be able to successfully develop new products or find a market for their sale.

•

As the cannabis market continues to mature, our products may become obsolete, less competitive, or less marketable.

•

Restrictions on branding and advertising may negatively impact our ability to attract and retain customers.

•

The cannabis business may be subject to unfavorable publicity or consumer perception.

•

Third parties with whom we do business may perceive themselves as being exposed to reputational risk by virtue of their relationship with us and may ultimately elect to discontinue their relationships with us.

•

There may be unknown health impacts associated with the use of cannabis and cannabis derivative products.

•

We may enter into strategic alliances or expand the scope of currently existing relationships with third parties that we believe

•

complement our business, financial condition and results of operation and there are risks associated with such activities.

•

Our success will depend on attracting and retaining key personnel.

•

Dependence on Senior Management.

•

Certain of our directors and officers may have conflicts of interests due to other business relationships.

•

Future execution efforts may not be successful.

•

We have expanded and intend to further expand our business and operations into jurisdictions outside of Canada, and there are risks associated with doing so.

•

Our business may be affected by political and economic instability, and a period of sustained inflation across the markets in which we operate could result in higher operating costs.

•

We rely on international advisors and consultants in foreign jurisdictions.

•

Failure to comply with the Corruption of Foreign Public Officials Act (Canada) (“CFPOA”) and the Foreign Corrupt Practices Act (U.S.) (“FCPA”), as well as the anti-bribery laws of the other nations in which we conduct business, could subject us to penalties and other adverse consequences.

•

We may be subject to uninsured or uninsurable risks.

•

We may be subject to product liability claims.

•

Our cannabis products may be subject to recalls for a variety of reasons.

•

We are and may become party to litigation, mediation, and/or arbitration from time to time.

•

The transportation of our products is subject to security risks and disruptions.

•

Our business is subject to the risks inherent in agricultural operations.

•

We have in the past, and may in the future, record significant impairments or write-downs of our assets.

•

Our operations are subject to various environmental and employee health and safety regulations.

•

Climate change may have an adverse effect on demand for our products or on our operations.

•

We may not be able to protect our intellectual property.

•

We may experience breaches of security at our facilities or in respect of electronic documents and data storage and may face risks related to breaches of applicable privacy laws.

•

We may be subject to risks related to our information technology systems, including cyber-attacks.

•

We may not be able to successfully identify and execute future acquisitions or dispositions, or to successfully manage the impacts of such transactions on our operations.

•

As a holding company, Aurora Cannabis Inc. is dependent on its operating subsidiaries to pay dividends and other obligations.

•

The price of our Common Shares has historically been volatile. This volatility may affect the value of your investment in Aurora, the price at which you could sell our Common Shares and the sale of substantial amounts of our Common Shares could adversely affect the price of our Common Shares and the value of your convertible debentures/notes.

•

It is not anticipated that any dividend will be paid to holders of our Common Shares for the foreseeable future.

•

Future sales or issuances of equity securities could decrease the value of our Common Shares, dilute investors’ voting power, and reduce our earnings per share.

•

Our management will have substantial discretion concerning the use of proceeds from future share sales and financing transactions.

•

The regulated nature of our business may impede or discourage a takeover, which could reduce the market price of our Common Shares and the value of any outstanding convertible debentures/notes.

•

There is no assurance we will meet or continue to meet, as applicable, the listing standards of NASDAQ and the TSX.

•

The financial reporting obligations of being a public company and maintaining a dual listing on the TSX and on Nasdaq requires significant company resources and management attention.

•

Failure to develop and maintain an effective system of internal controls increases the risk that we may not be able to accurately and reliably report our financial results or prevent fraud, which may harm our business, the trading price of our Common Shares and market value of other securities.

•

We are a Canadian company and shareholder protections may differ from shareholder protections in the U.S. and elsewhere.

 

•

•

We are a foreign private issuer within the meaning of the rules under the U.S. Exchange Act, and as such is exempt from certain provisions applicable to United States domestic issuers.

•

Our employees and counterparties may be subject to potential U.S. entry restrictions as a result of their relationship with us.

•

Participants in the cannabis industry may have difficulty accessing the service of banks and financial institutions, which may make it difficult for us to operate.

•

The Company’s employees, independent contractors and consultants may engage in fraudulent or other illegal activities.

•

Our business has and may continue to be subject to disruptions as a result of the COVID-19 pandemic.

•

Reliva’s operations in the U.S. may be impacted by regulatory action and approvals from the Food and Drug Administration.

•

The controversy surrounding vaporizers and vaporizer products may materially and adversely affect the market for vaporizer products and expose us to litigation and additional regulation.

•

We must rely largely on our own market research and internal data to forecast sales and market demand and market prices which may differ from our forecasts.

•

The Canadian excise duty framework affects profitability.

•

We may hedge or enter into forward sales, which involves inherent risks

•

The Company may be a passive foreign investment company, which may result in adverse U.S. federal income tax consequences for U.S. holders of Common Shares.

 

PFIC Risk

 

Generally, if for any taxable year 75% or more of the Company’s gross income is passive income, or at least 50% of the average quarterly value of the Company’s assets are held for the production of, or produce, passive income, the Company would be characterized as a passive foreign investment company (“PFIC”) for U.S. federal income tax purposes. Based on the current profile of the Company’s gross income, gross assets, the nature of its business, and its anticipated market capitalization, the Company believes that it may have been a PFIC for the 2022 taxable year. While it has not made a determination of expected PFIC status for the current taxable year, there is a risk that it may be a PFIC in the current taxable year and in the foreseeable future. Because PFIC status is determined on an annual basis and generally cannot be determined until the end of the taxable year, there can be no assurance that the Company will not be a PFIC for the current or future taxable years. If the Company is characterized as a PFIC, the Company’s shareholders who are U.S. holders may suffer adverse tax consequences, including the treatment of gains realized on the sale of the Common Shares as ordinary income, rather than as capital gain. A U.S. holder may be able to make a "qualified electing fund" election (a “QEF Election”) or, alternatively, a "mark-to-market" election that could mitigate the adverse U.S. federal income tax consequences that would otherwise apply to such U.S. holder. Upon request of a U.S. holder, the Company intends to provide the information necessary for a U.S. Holder to make applicable QEF Elections

 

Internal Controls over Financial Reporting

 

Disclosure Controls and Procedures

 

The Company maintains disclosure controls and procedures (“DC&P”) designed to provide reasonable assurance that information required to be disclosed in the Company’s annual filings, interim filings and other reports filed or submitted by it under securities laws is recorded, processed, summarized and reported accurately and in the time periods specified under such securities laws, and include controls and procedures designed to ensure such information is accumulated and communicated to the Company’s management, including its certifying officers, as appropriate to allow timely decisions regarding required disclosure. As at June 30, 2023, the CEO and CFO have concluded that the Company’s DC&P were not effective as at that date as a result of the material weakness identified as at March 31, 2023.

Changes in Internal Controls over Financial Reporting (“ICFR”)

In compliance with reporting obligations, management is in the process of assessing the effectiveness of ICFR pertaining to the Bevo AgTech Inc. business unit acquired on August 25, 2022, to be concluded upon as part of the ICFR assessment for the fiscal period ending March 31, 2024. Management, with oversight from the Audit Committee, also continues to implement remediation measures related to the material weakness as at March 31, 2023, with a focus on reducing the reliance on manual review procedures over data and information in key business processes, providing training to control owners, and enhancement to business processes and controls as the Company continues to mature its processes.

Aside from these initiatives, no changes were made during the first quarter to the Company’s ICFR that have materially affected, or is likely to materially affect, the Company’s ICFR. Management will continue to report changes to ICFR as well as progress with remediating the material weakness identified as at March 31, 2023.

 

Management’s Assessment on Internal Control over Financial Reporting

In accordance with National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings and as required by Rule 13a-15(f) and 15d-5(f) of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, management is responsible for establishing and maintaining adequate ICFR. The Company’s management, including the CEO and CFO, has designed ICFR based on the 2013 Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO Framework”) to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with IFRS.

 

ICFR is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. ICFR has inherent limitations. ICFR is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. ICFR also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by ICFR. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

 

Under the supervision and with the participation of our CEO and our CFO, management has ICFR based on the framework set forth in Internal Control - Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. A material weakness is a deficiency, or a combination of deficiencies, in ICFR, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. Management has concluded that a material weakness in the company’s ICFR continues to exist as identified and described in the Company’s annual reporting for the period ending March 31, 2023.

 

 

Management Review Controls: The Company did not consistently execute and document sufficiently precise management review controls, impacting impairment of goodwill, intangible assets and property, plant & equipment, lease accounting, business combinations and purchase price allocation, inventory provisioning, and financial statement close processes.

 

No material errors were identified in the consolidated annual financial statements as a result of the material weakness. This material weakness creates a reasonable possibility that material misstatements in interim or annual financial statements would not be prevented or detected on a timely basis.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This MD&A contains certain statements which may constitute “forward-looking information” and “forward-looking statements” within the meaning of Canadian securities law requirements (collectively, “forward-looking statements”). These forward-looking statements are made as of the date of this MD&A and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. Forward-looking statements relate to future events or future performance and reflect Company management’s expectations or beliefs regarding future events. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By their very nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The Company provides no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Forward-looking statements in this MD&A include, but are not limited to, statements with respect to:

 

•

pro forma measures including revenue, cash flow, adjusted gross margin before fair value adjustments, expected SG&A run-rates, and grams produced;

•

the Company’s ability to fund operating activities and cash commitments for investing and financing activities for the foreseeable future;

•

plans for the repurchase of convertible notes prior to maturity;

•

expectations regarding production capacity, costs and yields;

•

statements made under the heading “Our Strategy”;

•

statements made with respect to the anticipated disposition of legal claims disclosed under the heading “Contingencies”;

•

the Company’s strategy and path to deliver profitability and positive free cash flow;

•

the acquisition of Bevo and associated impact on revenue the creation of long-term value;

•

expectations for the plant propagation segment, including contributions from the Sky and Sun facilities;

•

future strategic opportunities;

•

growth opportunities including the expansion into additional international markets;

•

expectations related to the increased legalization of medical and consumer markets, including the United States;

•

the repositioning and improvements in the Company’s consumer business, and associated impact on future profitability and access to new global consumer markets as they open;

•

competitive advantages and strengths in Canadian and international medical cannabis, scientific leadership, multi-jurisdictional regulatory expertise , compliance, testing, cultivar breeding and product quality;

•

product portfolio and innovation, and associated revenue growth and impact on future long-term success;

•

expectations regarding biosynthetic production and associated intellectual property;

•

critical success factors in the cannabis industry, including profitable growth, positive cash flow, smart capital allocation and balance sheet health; and

•

the availability of funds under the Company’s 2023 Shelf Prospectus.

 

Forward looking information or statements contained in this document have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable.

 

Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management’s estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, management’s estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, COVID-19, and other risks as set out under “Risk Factors” contained herein. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements.

 

Although the Company believes that the expectations conveyed by the forward-looking statements are reasonable based on the information available to the Company on the date hereof, no assurance can be given as to future results, approvals or achievements. Forward-looking statements contained in this MD&A and in the documents incorporated by reference herein are expressly qualified by this cautionary statement.

 

 

Cautionary Statement Regarding Certain Non-GAAP Performance Measures

 

This MD&A contains certain financial performance measures that are not recognized or defined under IFRS (“Non-GAAP Measures”). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. For an explanation of these measures to related comparable financial information presented in the consolidated Financial Statements prepared in accordance with IFRS, refer to the discussion below. The Company believes that these Non-GAAP Measures are useful indicators of operating performance and are specifically used by management to assess the financial and operational performance of the Company. These Non-GAAP Measures include, but are not limited, to the following:

 

•

Cannabis net revenue represents revenue from the sale of cannabis products, excluding excise taxes. Cannabis net revenue is further broken down as follows:

o

Medical cannabis net revenue represents Canadian and international cannabis net revenue for medical cannabis sales only.

o

Consumer cannabis net revenue represents cannabis net revenue for consumer cannabis sales only.

o

Wholesale bulk cannabis net revenue represents cannabis net revenue for wholesale bulk cannabis only.

o

Management believes the cannabis net revenue measures provide more specific information about the net revenue purely generated from our core cannabis business and by market type.

•

Average net selling price of dried cannabis excluding bulk sales, is calculated by taking net revenue from dried cannabis, less net revenue from wholesale bulk cannabis sold in the period, which is then divided by total grams and gram equivalent of cannabis sold in the period. Management believes the average net selling price per gram or gram equivalent measure provides more specific information about the pricing trends over time

•

Gross profit and margin before FV adjustments on cannabis net revenue is calculated by subtracting (i) cost of sales, before the effects of changes in FV of biological assets and inventory, and (ii) cost of sales from plant propagation ancillary support functions, from total cannabis net revenue. Gross margin before FV adjustments on cannabis net revenue is calculated by dividing gross profit before FV adjustments on cannabis net revenue divided by cannabis net revenue. Management believes that these measures provide useful information to assess the profitability of our cannabis operations as it excludes the effects of non-cash FV adjustments on inventory and biological assets, which are required by IFRS.

•

Adjusted gross profit and margin before FV adjustments on cannabis net revenue represents cash gross profit and gross margin on cannabis net revenue and is calculated by subtracting from total cannabis net revenue (i) cost of sales, before the effects of changes in FV of biological assets and inventory; (ii) cost of sales from plant propagation ancillary support functions; and removing (iii) depreciation in cost of sales; (iv) cannabis inventory impairment; and (v) business transformation, non-recurring, and out-of-period adjustments. Adjusted gross margin before FV adjustments on cannabis net revenue is calculated by dividing adjusted gross profit before FV adjustments on cannabis net revenue divided by cannabis net revenue. Adjusted gross profit and gross margin before FV adjustments on cannabis net revenue is further broken down as follows:

o

Adjusted gross profit and gross margin before FV adjustments on medical cannabis net revenue represents gross profit and gross margin before FV adjustments on sales generated in the medical market only.

o

Adjusted gross profit and gross margin before FV adjustments on consumer cannabis net revenue represents gross profit and gross margin before FV adjustments on sales generated in the consumer market only.

o

Adjusted gross profit and gross margin before FV adjustments on wholesale bulk cannabis net revenue represents gross profit and gross margin before FV adjustments on sales generated from wholesale bulk cannabis only.

o

Management believes that these measures provide useful information to assess the profitability of our cannabis operations as it represents the cash gross profit and margin generated from cannabis operations and excludes (i) out-of-period adjustments to provide information that reflects current period results; and (ii) excludes the effects of non-cash FV adjustments on inventory and biological assets, which are required by IFRS.

•

Adjusted EBITDA is calculated as net income (loss) from continuing operations excluding income tax expense (recovery), other income (expenses), share-based compensation, depreciation and amortization, acquisition costs, changes in fair value of inventory sold, inventory impairment adjustments, changes in fair value of biological assets, costs related to our business transformation, out-of-period adjustments, non-recurring items and costs related to business operations focused on developing international markets prior to commercialization. Adjusted EBITDA is intended to provide a proxy for the Company’s operating cash flow and is widely used by industry analysts to compare Aurora to its competitors, and derive expectations of future financial performance for Aurora, and excludes out-of-period adjustments that are not reflective of current operating results.

•

Management believes that working capital is an important liquidity measure and is defined as current assets less current liabilities as stated on the Company’s Consolidated Statements of Financial Position.

•

Adjusted SG&A is defined as SG&A, less business transformation, non-recurring, market development, and out-of-period costs. Management believes this measure provides useful information to assess the recurring costs of our operations.

•

Adjusted R&D is defined as R&D, less business transformation, non-recurring and out-of-period costs. Management believes this measure provides useful information to assess the recurring costs of our operations.

 

Non-GAAP Measures should be considered together with other data prepared accordance with IFRS to enable investors to evaluate the Company’s operating results, underlying performance and prospects in a manner similar to Aurora’s management. Accordingly, these Non-GAAP Measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

 

 

 

26  | AURORA CANNABIS INC.      Q1 2024 MD&A

Exhibit 99.3

 

 

 

Form 52-109F2

Certification of Interim Filings

Full Certificate

 

I, Miguel Martin, Chief Executive Officer of Aurora Cannabis Inc., certify the following:

1.

Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Aurora Cannabis Inc. (the “issuer”) for the interim period ended June 30, 2023.

 

2.

No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

 

3.

Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

 

4.

Responsibility: The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.

 

5.

Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings

 

(a)

designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

 

(i)

material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

 

(ii)

information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

 

(b)

designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

 

5.1

Control framework: The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is the Internal Control - Integrated Framework (COSO Framework 2013) published by The Committee of Sponsoring Organization of the Treadway Commission (COSO).

 

5.2

ICFR - material weakness relating to design: The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period:

 

(a)

a description of the material weakness;

 

(b)

the impact of the material weakness on the issuer’s financial reporting and its ICFR; and

 

(c)

the issuer’s current plans, if any, or any actions already undertaken, for remediating the material weakness.

 

5.3

Limitation on scope of design: N/A

 

6.

Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on April 1, 2023 and ended on June 30, 2023 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

 

Date: August 10, 2023

 

/s/ Miguel Martin                                  

Miguel Martin

Chief Executive Officer

 

 

Exhibit 99.4

 

 

Form 52-109F2

Certification of Interim Filings

Full Certificate

 

I, Glen Ibbott, Chief Financial Officer of Aurora Cannabis Inc., certify the following:

1.

Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Aurora Cannabis Inc. (the “issuer”) for the interim period ended June 30, 2023.

 

2.

No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

 

3.

Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

 

4.

Responsibility: The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.

 

5.

Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings

 

(a)

designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

 

(i)

material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

 

(ii)

information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

 

(b)

designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

 

5.1

Control framework: The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is the Internal Control - Integrated Framework (COSO Framework 2013) published by The Committee of Sponsoring Organization of the Treadway Commission (COSO).

 

5.2

ICFR - material weakness relating to design: The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period:

 

(a)

a description of the material weakness;

 

(b)

the impact of the material weakness on the issuer’s financial reporting and its ICFR; and

 

(c)

the issuer’s current plans, if any, or any actions already undertaken, for remediating the material weakness.

 

5.3

Limitation on scope of design: N/A

 

6.

Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on April 1, 2023 and ended on June 30, 2023 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

 

Date: August 10, 2023

 

/s/ Glen Ibbott                                            

Glen Ibbott

Chief Financial Officer

 

 

---